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1INTRODUCTION
The term subclinical hypothyroidism was originally used to describe the patient
with a low- normal free T4 but a slightly elevated serum TSH level. Other terms
for this condition are mild hypothyroidism early thyroid failure, preclinical
hypothyroidism, and decreased thyroid reserve. The TSH elevation in such patients
is modest, with values typically between 4 and 15 mU/L, although patients with a
TSH above 10 mU/L more often have a reduced free T4 and may have some
hypothyroid symptoms. The definition of this syndrome depends significantly on
the reference range for a normal TSH concentration. This syndrome is most often
seen in patients with early Hashimoto's disease and is a common phenomenon,
occurring in 7% to 10% of older women.1,2,3 The common etiology of this disease
are not sufficiently treated cases of hypothyroidism and disease of the gland caused
by autoimmunity. The existence of antibodies against the gland point out the
existence of autoimmune disease of the gland. Other etiologies for this disease are
those cases of hyperthyroidism who have undergone therapy in the past, those who
have undergone radiation treatment to the neck in the past and also undergone
therapy like with cytokines, therapy with iodine, therapy with lithium, with drugs
like amiodarone and also the thyroiditis which develops after delivery which has
got a hypothyroid period [4]. Subclinical hypothyroidism is very commonly
encountered in the community showing a prevalence rate of three to eight percent
2where previously no disease of the thyroid has been shown to occur [2,5]. There is a
rise seen in the prevalence as the age progresses and also more case is seen in
females.2
Also prevalence of subclinical hypothyroidism is more in females than in males
and also in older people than in younger people because of the fact that the
prevalence of thyroglobulin and thyroid peroxidase ( microsomal ) antibodies is
higher in females and in older people. Subjects due to subclinical hypothyroidism
show an increased rate at which they convert into clinical hypothyroidism about
2.6 % every year in cases when the thyroperoxidase have antibodies against them
not present and 4.3 percent if they have it [6]. However it has been shown that some
people do not manifest clinical hypothyroidism while others return to normal level.
 A thyroid stimulating hormone value more than 10 mIU/L mostly manifest
clinical hypothyroidism while value below 6 mIU/L less frequently manifest. It has
been shown in one of the trials in both males and females above fifty five years
and followed up for a mean period of thirty two months, the thyroid stimulating
hormone values returned to normal in fifty two percent of subjects who had the
hormone below 10 mIU/L7.  Even though it has been agreed that hypothyroidism
results in increase in the cholesterol levels in the patient there by causing
atherosclerosis[8], it has been found out from various studies that the correlation
between increased lipids, atherosclerosis and subclinical hypothyroidism resulted
3in not so convincing outcome. While some studies showed that there are large
number of hypercholesterolemic patients in SH while some other studies showed
that SH patients develop only modest in the range of only 10% higher average in
terms of total cholesterol than subjects not having the disease [9-22]. In the first
Whickham study it was shown that the cholesterol levels did not show any
association with regard to the increase in thyroid stimulating hormone after the
researchers adjusted the subjects for age [11]. Also after that the Whickham survey
showed that there is no relation between the increased thyroid stimulating hormone
and increased probability of suffering from ischemic disease of the heart or
abnormality in serum lipid levels [23]. Therefore it can be said that from the
discussions above the relationship between subclinical hypothyroidism and
cardiovascular disease remains controversial. However there was no difference
between women with subclinical hypothyroidism and controls regarding
hypertension and diabetes mellitus 21,24. This study was done to find out the
prevalence of subclinical hypothyroidism and its relation to Hypertension,
Diabetes and Ischemic heart disease among women above the age of   50 years
attending medical outpatient clinic at Government chengalpattu medical college
and hospital.
4AIM OF THE STUDY
• To find out the prevalence of subclinical hypothyroidism among women above
50 years of age.
• To study the relation between subclinical hypothyroidism and Hypertension,
Diabetes and Ischemic Heart Disease in those patients.
5REVIEW OF LITERATURE
PHYLOGENY, EMBRYOLOGY, AND ONTOGENY  [25]
Phylogeny
The phylogeny, embryogenesis, and certain aspects of thyroid function are closely
interlinked with the gastrointestinal tract. Monoiodotyrosine (3'-monoiodo-l-
tyrosine [MIT]) and diiodotyrosine (3,5'-diiodo-l-tyrosine [DIT]) are present in a
variety of invertebrate species, including mollusks, crustaceans, coelenterates,
annelids, insects, and certain marine algae. In these lower forms, however, no
recognizable thyroid tissue is present. Thyroid gland is found in all vertebrates and
confined to them. Other glands which concentrate iodide in their secretions are the
gastric and salivary glands.
Structural Embryology
The human thyroid anlage is first recognizable at E16-17. The thyroid gland
develops from the floor of the primitive pharynx during the third week of
gestation. The developing gland migrates along the thyroglossal duct to reach its
final location in the neck. Thyroid hormone synthesis normally begins at about 11
weeks' gestation. Neural crest derivatives from the ultimobranchial body give rise
to thyroid medullary C cells that produce calcitonin, a calcium-lowering
hormone.The C cells are interspersed throughout the thyroid gland, although their
6density is greatest in the juncture of the upper one-third and lower two-thirds of the
gland.Thyroid gland development is orchestrated by the coordinated expression of
several developmental transcription factors. Thyroid transcription factor (TTF)-1,
TTF-2, and paired homeobox-8 (PAX-8) are expressed selectively, but not
exclusively, in the thyroid gland. In combination, they dictate thyroid cell
development and the induction of thyroid-specific genes such as thyroglobulin
(Tg), thyroid peroxidase (TPO), the sodium iodide symporter (Na+/I, NIS), and the
thyroid-stimulating hormone receptor (TSH-R).
Functional Ontogeny
The ontogeny of thyroid function and its regulation in the human fetus are fairly
well defined. Future follicular cells acquire the capacity to form thyroglobulin (Tg)
as early as the 29th day of gestation, whereas the capacities to concentrate iodide
and synthesize thyroxine (T4) are delayed until about the 11th week. Radioactive
iodine inadvertently given to the mother would be accumulated by the fetal thyroid
soon thereafter. Early growth and development of the thyroid do not seem to be
TSH-dependent, because the capacity of the pituitary to synthesize and secrete
TSH is not apparent until the 14th week. Subsequently, rapid changes in pituitary
and thyroid function take place. Probably as a consequence of hypothalamic
maturation and increasing secretion of thyrotropin-releasing hormone (TRH), the
serum TSH concentration increases between 18 and 26 weeks' gestation, after
7which levels remain higher than those in the mother. The higher levels may reflect
a higher set-point of the negative feedback control of TSH secretion during
fetal life than at maturity. Thyroxine-binding globulin (TBG), the major thyroid
hormone–binding protein in plasma, is detectable in the serum by the 10th
gestational week and increases in concentration progressively to term. This
increase in TBG concentration accounts in part for the progressive increase in
the serum T4 concentration during the second and third trimesters, but increased
secretion of T4 must also play a role because the concentration of  free T4 also
rises.  Several  aspects  of  thyroid  development  are  of  note  from  the  clinical
standpoint. Rarely, thyroid tissue may develop from remnants of the thyroglossal
duct near the base of the tongue. Such lingual thyroid tissue may be the sole
functioning thyroid present and, thus, its surgical removal will lead to
hypothyroidism. More commonly, elements of the thyroglossal duct may persist
and later give rise to thyroglossal duct cysts, or ectopic thyroid tissue may be
present at any location in the mediastinum or, rarely, even in the heart.
ANATOMY AND HISTOLOGY [26]
The number of lobes in the gland is two and they are joined by a piece of the gland
called the isthmus. The gland is present in front of the trachea. It is situated in the
neck with the cricoid at the top and down below is suprasternal notch. The gland
usually weighs about twelve to twenty grams.The superior and inferior thyroid
8artery supplies blood. There are 4 parathyroid glands, the source of parathyroid
hormone and are situated behind the gland’s poles. One important structure which
needs to be watched carefully during surgery of the gland is recurrent laryngeal
nerve which courses by the side of the gland and they are frequently injured
leading to the paralysis of the cord. The thyroid gland consists of numerous
spherical follicles composed of thyroid follicular cells that surround secreted
colloid, a proteinaceous fluid containing large amounts of thyroglobulin, precursor
of thyroid hormones. The thyroid follicular cells are polarized—the basolateral
surface is apposed to the bloodstream and an apical surface faces the follicular
lumen. Increased demand for thyroid hormone is regulated by thyroid-stimulating
hormone (TSH), which binds to its receptor on the basolateral surface of the
follicular cells, leading to Tg reabsorption from the follicular lumen, proteolysis
within the cytoplasm, yielding thyroid hormones for secretion into the
bloodstream.
IODINE AND THE SYNTHESIS AND SECRETION OF THYROID [26]
HORMONES
Thyroid Hormone Synthesis
The hormones of the gland are made from thyroglobulin. After thyroglobulin is
poured into follicles of the gland, iodine is attached to tyrosine residues and these
9are joined by ether linkage. When the thyroglobulin is once again taken back into
the follicles of the gland and proteolysis occurs and the newly made T4, T3 are
released.
Iodine Metabolism and Transport
One of the first important steps in the production of thyroid hormone is taking up
of the iodide. The iodine which we take through diet is attached to the proteins
present in the serum, mainly albumin. The iodine which is not bound gets out of
the body in urine. The iodine present in the blood is efficiently caught by the gland.
Sodium/iodine symporter (NIS) which carries out the process of taking up the
iodide is present in basolateral membrane in the follicles of the gland. NIS is
mainly found in thyroid but less of it is found in structures like salivary gland, milk
secreting mammary glands and placenta. The presence of less iodine results in
more NIS being expressed, whereas high iodine levels suppress NIS expression
and uptake. The selective expression of NIS in the thyroid allows isotopic
scanning, treatment of hyperthyroidism, and ablation of thyroid cancer with
radioisotopes of iodine, without significant effects on other organs. Mutation of the
NIS gene is a rare cause of congenital hypothyroidism, underscoring its importance
in thyroid hormone synthesis. Another iodine transporter, pendrin, is located on the
apical surface of thyroid cells and mediates iodine efflux into the lumen. Mutations
of the pendrin gene causes pendred syndrome, a disorder characterized by
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defective organification of iodine, goiter and sensorineural deafness. Iodine
deficiency is prevalent in many mountainous regions. The World Health
Organization (WHO) estimates that about 2 billion people are iodine-deficient,
based on urinary excretion data. In areas of relative iodine deficiency, there is an
increased prevalence of goiter and, when deficiency is severe, hypothyroidism and
cretinism. Cretinism is characterized by mental and growth retardation and occurs
when children who live in iodine-deficient regions are not treated with iodine or
thyroid hormone to restore normal thyroid hormone levels during early life. These
children are often born to mothers with iodine deficiency, and it is likely that
maternal thyroid hormone deficiency worsens the condition. Concomitant selenium
deficiency may also contribute to the neurologic manifestations of cretinism.
Iodine supplementation of salt, bread, and other food substances has markedly
reduced the prevalence of cretinism. Unfortunately, however, iodine deficiency
remains the most common cause of preventable mental deficiency, often because
of societal resistance to food additives or the cost of supplementation. In addition
to overt cretinism, mild iodine deficiency can lead to subtle reduction of IQ.
Oversupply of iodine, through supplements or foods enriched in iodine (e.g.,
shellfish, kelp), is associated with an increased incidence of autoimmune thyroid
disease. The recommended average daily intake of iodine is 150–250 ?g/d for
11
adults, 90–120 ?g/d for children, and 250 ?g/d for pregnant and lactating women.
Urinary iodine is >10 ?g/dL in iodine-sufficient populations.
Organification, Coupling, Storage, Release
After iodide enters the thyroid, it is trapped and transported to the apical membrane
of thyroid follicular cells, where it is oxidized in an organification reaction that
involves TPO and hydrogen peroxide. The reactive iodine atom is added to
selected tyrosyl residues within Tg. The iodotyrosines in Tg are then coupled via
an ether linkage in a reaction that is also catalyzed by TPO. Either T4 or T3 can be
produced by this reaction, depending on the number of iodine atoms present in the
iodotyrosines. After coupling, Tg is taken back into the thyroid cell, where it is
processed in lysosomes to release T4 and T3. Uncoupled mono- and diiodotyrosines
(MIT, DIT) are deiodinated by the enzyme dehalogenase, thereby recycling any
iodide that is not converted into thyroid hormones. Disorders of thyroid hormone
synthesis are rare causes of congenital hypothyroidism. The vast majority of these
disorders are due to recessive mutations in TPO or Tg, but defects have also been
identified in the TSH-R, NIS, pendrin, hydrogen peroxide generation, and
dehalogenase. Because of the biosynthetic defect, the gland is incapable of
synthesizing adequate amounts of hormone, leading to increased TSH and a large
goiter.
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TSH Action
TSH regulates thyroid gland function through the TSH-R, a seven-transmembrane
G protein–coupled receptor (GPCR). The TSH-R is coupled to the subunit of
stimulatory G protein (Gs), which activates adenylyl cyclase, leading to increased
production of cyclic AMP. TSH also stimulates phosphatidylinositol turnover by
activating phospholipase C. The functional role of the TSH-R is exemplified by the
consequences of naturally occurring mutations. Recessive loss-of-function
mutations cause thyroid hypoplasia and congenital hypothyroidism. Dominant
gain-of-function mutations cause sporadic or familial hyperthyroidism that is
characterized by goiter, thyroid cell hyperplasia, and autonomous function. Most of
these activating mutations occur in the transmembrane domain of the receptor.
They mimic the conformational changes induced by TSH binding or the
interactions of thyroid-stimulating immunoglobulins (TSI) in Graves' disease.
Activating TSH-R mutations also occur as somatic events, leading to clonal
selection and expansion of the affected thyroid follicular cell and autonomously
functioning thyroid nodules.
Other Factors playing a role in hormone production and it’s release
Although TSH is the dominant hormonal regulator of thyroid gland growth and
function, a variety of growth factors, most produced locally in the thyroid gland,
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also influence thyroid hormone synthesis. These include insulin-like growth factor
I (IGF-1), epidermal growth factor, transforming growth factor (TGF-),
endothelins, and various cytokines. The quantitative roles of these factors are not
well understood, but they are important in selected disease states. Certain cytokines
and interleukins (ILs) produced in association with autoimmune thyroid disease
induce thyroid growth, whereas others lead to apoptosis. In acromegaly, increased
levels of growth hormone and IGF-1 are associated with goiter and predisposition
to multinodular goiter (MNG). Iodine deficiency increases thyroid blood flow and
upregulates the NIS, stimulating more efficient iodine uptake. Excess iodide
transiently inhibits thyroid iodide organification, a phenomenon known as the
Wolff-Chaikoff effect. In individuals with a normal thyroid, the gland escapes
from this inhibitory effect and iodide organification resumes; the suppressive
action of high iodide may persist, however, in patients with underlying
autoimmune thyroid disease.
Thyroid Hormone Transport and Metabolism [26]
SERUM BINDING PROTEINS
T4 is secreted from the thyroid gland in about twentyfold excess over T3. Both
hormones are bound to plasma proteins, including thyroxine-binding globulin
(TBG), transthyretin (TTR, formerly known as thyroxine-binding prealbumin, or
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TBPA), and albumin. The plasma-binding proteins increase the pool of circulating
hormone, delay hormone clearance, and may modulate hormone delivery to
selected tissue sites. The concentration of TBG is relatively low (1–2 mg/dL), but
because of its high affinity for thyroid hormones (T4 > T3), it carries about 80% of
the bound hormones. Albumin has relatively low affinity for thyroid hormones but
has a high plasma concentration (3.5 g/dL), and it binds up to 10% of T4 and 30%
of T3. TTR carries about 10% of T4 but little T3. Approximately 99.98% of T4 and
99.7%  of  T3 are protein-bound. Because T3 is less tightly bound than T4, the
fraction of unbound T3 is greater than unbound T4, but there is less unbound T3 in
the circulation because it is produced in smaller amounts and cleared more rapidly
than T4. The unbound or "free" concentrations of the hormones are 2 × 1011M for
T4 and  6  ×  1012M for  T3, which roughly correspond to the thyroid hormone
receptor binding constants for these hormones. The unbound hormone is thought to
be biologically available to tissues. Nonetheless, the homeostatic mechanisms that
regulate the thyroid axis are directed toward maintenance of normal concentrations
of unbound hormones.
DEIODINASES
T4 may be thought of as a precursor for the more potent T3. T4 is converted to T3
by the deiodinase enzymes. Type I deiodinase, which is located primarily in
thyroid, liver, and kidneys, has a relatively low affinity for T4. Type II deiodinase
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has a higher affinity for T4 and is found primarily in the pituitary gland, brain,
brown fat, and thyroid gland. Expression of type II deiodinase allows it to regulate
T3 concentrations locally. Type II deiodinase is also regulated by thyroid hormone;
hypothyroidism induces the enzyme, resulting in enhanced T4 to T3 conversion in
tissues such as brain and pituitary. T4 to  T3 conversion is impaired by fasting,
systemic illness or acute trauma, oral contrast agents, and a variety of medications
(e.g., propylthiouracil, propranolol, amiodarone, glucocorticoids). Type III
deiodinase inactivates T4 and T3 and is the most important source of reverse T3
(rT3). Massive hemangiomas that express type III deiodinase are a rare cause of
hypothyroidism in infants.
Thyroid Hormone Action [26]
THYROID HORMONE TRANSPORT
Circulating thyroid hormones enter cells by passive diffusion and via specific
transporters such as the monocarboxylate 8 (MCT8) transporter. Mutations in the
MCT8 gene have been identified in patients with X-linked psychomotor
retardation and thyroid function abnormalities (low T4, high T3, and high TSH).
After entering cells, thyroid hormones act primarily through nuclear receptors,
although they also have nongenomic actions through stimulating plasma membrane
and mitochondrial enzymatic responses.
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NUCLEAR THYROID HORMONE RECEPTORS
Thyroid hormones bind with high affinity to nuclear thyroid hormone receptors
TRs) ? and ?. Both TR ? and TR ? are expressed in most tissues, but their relative
expression levels vary among organs; TR ? is particularly abundant in brain,
kidneys, gonads, muscle, and heart, whereas TR ? expression is relatively high in
the pituitary and liver. Both receptors are variably spliced to form unique isoforms.
The TR ?2 isoform, which has a unique amino terminus, is selectively expressed in
the hypothalamus and pituitary, where it plays a role in feedback control of the
thyroid axis. The TR ?2 isoform contains a unique carboxy terminus that precludes
thyroid hormone binding; it may function to block the action of other TR isoforms.
The receptors contain a domain in the central region of DNA for binding and
another region for binding in the C- terminal ligand. It results in binding to specific
DNA sequences, termed thyroid response elements (TREs), in the promoter
regions of target genes.  The receptors bind as homodimers or, more commonly, as
heterodimers with retinoic acid X receptors (RXRs). The activated receptor can
either stimulate gene transcription (e.g., myosin heavy chain ?) or inhibit
transcription (e.g., TSH ? -subunit gene), depending on the nature of the regulatory
elements in the target gene. Thyroid hormones (T3 and  T4)  bind  with  similar
affinities to TR ? and TR ?. However, structural differences in the ligand binding
domains provide the potential for developing receptor-selective agonists or
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antagonists. T3 is bound with 10–15 times greater affinity than T4, which explains
its increased hormonal potency. Though T4 is produced in excess of T3, receptors
are occupied mainly by T3, reflecting T4 to  T3 conversion by peripheral tissues,
greater T3 bioavailability in the plasma, and receptors' greater affinity for T3. After
binding to TRs, thyroid hormone induces conformational changes in the receptors
that modify its interactions with accessory transcription factors. Importantly, in the
absence of thyroid hormone binding, the aporeceptors bind to co-repressor proteins
that inhibit gene transcription. Hormone binding dissociates the co-repressors and
allows the recruitment of coactivators that enhance transcription. The discovery of
TR interactions with corepressors explains the fact that TR silences gene
expression in the absence of hormone binding. Consequently, hormone deficiency
has a profound effect on gene expression because it causes gene repression as well
as loss of hormone-induced stimulation. This concept has been corroborated by the
finding that targeted deletion of the TR genes in mice has a less-pronounced
phenotypic effect than hormone deficiency.
THYROID HORMONE RESISTANCE
Resistance to thyroid hormone (RTH) is an autosomal dominant disorder
characterized by elevated thyroid hormone levels and inappropriately normal or
elevated TSH. Individuals with RTH do not, in general, exhibit signs and
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symptoms that are typical of hypothyroidism because hormone resistance is partial
and is compensated by increased levels of thyroid hormone. The clinical features
of RTH can include goiter, attention deficit disorder, mild reduction in IQ, delayed
skeletal maturation, tachycardia, and impaired metabolic responses to thyroid
hormone. RTH is caused by mutations in the TR ? receptor gene. These mutations,
located in restricted regions of the ligand-binding domain, cause loss of receptor
function. However, because the mutant receptors retain the capacity to dimerize
with RXRs, bind to DNA, and recruit co-repressor proteins, they function as
antagonists of the remaining normal TR ? and TR ? receptors. This property,
referred to as "dominant negative" activity, explains the autosomal dominant mode
of transmission. The diagnosis is suspected when unbound thyroid hormone levels
are increased without suppression of TSH. Similar hormonal abnormalities are
found in other affected family members, although the TR ? mutation arises de
novo in about 20% of patients. DNA sequence analysis of the TR ? gene provides
a definitive diagnosis. RTH must be distinguished from other causes of euthyroid
hyperthyroxinemia and inappropriate secretion of TSH by TSH-secreting pituitary
adenomas. In most patients, no treatment is indicated; the importance of making
the diagnosis is to avoid inappropriate treatment of mistaken hyperthyroidism and
to provide genetic counseling.
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Physical Examination
In addition to the examination of the thyroid itself, the physical examination should
include a search for signs of abnormal thyroid function and the extrathyroidal
features of ophthalmopathy and dermopathy. Examination of the neck begins by
inspecting the seated patient from the front and side and noting any surgical scars,
obvious masses, or distended veins. The thyroid can be palpated with both hands
from behind or while facing the patient, using the thumbs to palpate each lobe. It is
best to use a combination of these methods, especially when nodules are small. The
patient's neck should be slightly flexed to relax the neck muscles. After locating
the cricoid cartilage, the isthmus can be identified and followed laterally to locate
either lobe (normally, the right lobe is slightly larger than the left). By asking the
patient to swallow sips of water, thyroid consistency can be better appreciated as
the gland moves beneath the examiner's fingers. Features to be noted include
thyroid size, consistency, nodularity, and any tenderness or fixation. An estimate of
thyroid size (normally 12–20 g) should be made, and a drawing is often the best
way to record findings. However, ultrasound is the method of choice when it is
important to determine thyroid size accurately. The size, location, and consistency
of any nodules should also be defined. A bruit over the gland indicates increased
vascularity, as occurs in hyperthyroidism. If the lower borders of the thyroid lobes
are not clearly felt, a goiter may be retrosternal. Large retrosternal goiters can
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cause venous distention over the neck and difficulty breathing, especially when the
arms are raised (Pemberton's sign). With any central mass above the thyroid, the
tongue should be extended, as thyroglossal cysts then move upward. The thyroid
examination is not complete without assessment for lymphadenopathy in the
supraclavicular and cervical regions of the neck.
REGULATION OF THE THYROID AXIS [26]
TSH, secreted by the thyrotrope cells of the anterior pituitary, plays a pivotal role
in control of the thyroid axis and serves as the most useful physiologic marker of
thyroid hormone action. TSH is a 31-kDa hormone composed of ? and ? subunits.
Hypothalamic TRH stimulates pituitary production of TSH, which, in turn,
stimulates thyroid hormone synthesis and secretion. Thyroid hormones, acting
predominantly through thyroid hormone receptor ?2 (TR ? 2), feed back to inhibit
TRH and TSH production. The "set-point" in this axis is established by TSH. TRH
is the major positive regulator of TSH synthesis and secretion. Reduced levels of
thyroid hormone increase basal TSH production and enhance TRH-mediated
stimulation of TSH. High thyroid hormone levels rapidly and directly suppress
TSH gene expression secretion and inhibit TRH stimulation of TSH, indicating
that thyroid hormones are the dominant regulator of TSH production. Like other
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pituitary hormones, TSH is released in a pulsatile manner and exhibits a diurnal
rhythm; its highest levels occur at night.
LABORATORY ASSESSMENT OF THYROID STATUS [25]
Tests of the Hypothalamic-Pituitary-Thyroid Axis
While an inherently indirect reflection of thyroid hormone supply, tests that assess
the state of the hypothalamic-pituitary-thyroid axis play a critical role in the
diagnosis of thyroid disease. This is because the rate of TSH secretion is
exquisitely sensitive to the plasma concentrations of free thyroid hormones thus
providing a precise and specific barometer of the thyroid status of the patient.
Immunometric assay technology now makes it possible to define the normal range
for serum TSH and hence to ascertain both when thyroid function is inadequate or
when the hormone supply is excessive. This assay uses the TSH molecule as a link
between a TSH antibody bound to an inert surface (e.g., particles, the side of a test
tube) and a second antibody directed against a different TSH epitope that is labeled
with a detectable marker (I 125, an enzyme, or a chemiluminescent reagent). Thus,
the signal generated is proportional to the concentration of TSH in the serum. This
technique is more specific, sensitive, and rapid than radioimmunoassay. The serum
TSH normal range by immunometric assay differs slightly in different labs but is
most commonly 0.4 to 4.2mU/L. It should be kept in mind that there is a diurnal
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variation of TSH secretion with peak values in the early evening and a nadir in the
afternoon. A borderline abnormal value should always be repeated within a period
of a week or so to be certain that it is representative. A minimally suitable TSH
assay should be able to quantitate concentrations of TSH of 0.1 mU/L with a
coefficient of variation of less than 20%.  TSH ?-subunit is not detectable in serum
but the ?-subunit which is common to FSH, hCG, TSH and LH is detectable with a
normal range of 1 to 5?g/L. When FSH and LH production are increased, as in
postmenopausal women, or when TSH production is increased, as in primary
hypothyroidism, the free a-subunit level is also increased. The a-subunit level may
also be increased in patients with glycoprotein producing tumors of the anterior
pituitary. Its measurement may be useful in the rare patient with hyperthyroidism
and a normal or elevated TSH to differentiate between neoplastic and
nonneoplastic causes of TSH excess.
TSH in Patients with Thyroid Dysfunction
Patients with thyrotoxicosis which is due to excess thyroid hormone from any
cause and/or hyperthyroidism which is due to excess secretion of thyroid hormone
will virtually be characterised by a subnormal TSH. Patients with pituitary or
hypothalamic hypothyroidism is often characterised by a normal or even slightly
elevated serum TSH. In general, the degree of TSH elevation correlates with the
clinical severity of the hypothyroidism. Patients with serum TSH values in the
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range of 5 to 15 mU/L have few if any symptoms,[27] and the serum free T4 or free
T4 index (F T4I) is typically low-normal while serum free T3 concentrations are
normal.[28] [29] Such individuals with modest TSH elevation are said to have
subclinical hypothyroidism if  the  serum  free  T4  is  in  the  normal  range.  An
elevation in both serum TSH and free T4 is unusual and indicates either
autonomous TSH production as with a TSH-secreting pituitary tumor, resistance to
thyroid hormone (RTH), or hyperthyroidism with an artifactual elevation in TSH.
QUANTITATION OF SERUM THYROID HORMONE
CONCENTRATIONS
Total T4 and T3
Quantitation  of  the  circulating  thyroid  hormone  concentrations  is  essential  to
confirm that the thyroid status abnormality suggested by an abnormal TSH result is
accurate as well as documenting its severity. Sensitive and specific
radioimmunoassays are available for measuring the total concentrations of T4 and
T3 and some of their metabolic by-products. Because the thyroid status correlates
with the free, rather than with the total, hormone concentration, the physician must
also  obtain  some  estimate  of  that.  The  degree  of  abnormality  in  the  free  T4
generally correlates with the severity of the hormone excess or deficiency, whereas
the serum TSH concentration is an indication of the impact of this abnormality in
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that specific patient. The normal range for serum T3 concentration is 1.1 to 2.9
nmol/L (70 to 190 ng/dL). The normal total T4 is 64 to 142 nmol/L (5 to 11
?g/dL).
Concentrations of Free T4 and T3.
The normal ranges for free T4 and T3 are 9 to 30 pmol/L (0.7 to 2.5 ng/dL) and for
free T3, 3 to 8 pmol/L (0.2 to 0.5 ng/dL). Because T4 is the major secretory
product of the thyroid and correlates most closely with the serum TSH, in most
situations, a free T4 estimate is all that is required to ascertain the state of thyroid
secretion or supply. An array of methods is used to quantitate free T4 (or T3) in
whole serum using automated methods.[30] There are two general categories of
methods: free T4 index methods and comparative free T4 methods. Three general
approaches are used: (1) two-step labeled hormone methods, (2) one-step labeled
analogue methods, and (3) labeled antibody approaches. In general, two-step
labeled hormone back titration methods are less subject to artifacts due to
abnormal binding proteins, changes in albumin, TBG, or increases in free fatty
acids than are one-step hormone analogue methods.[31] [32] [33] . Thus, the clinician
must be wary if the free T4 result by any method does not agree with the clinical
state and the TSH. In such cases, another method should be used to estimate the
free T4, such as quantitation of T4 in a dialysate or ultrafiltrate, the free T4 index
should be measured, or the result should be ignored. For pregnant or severely ill
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patients, the automated methods typically give falsely low results, particularly if
these are performed using one-step procedures. A reasonable alternative for
pregnancy is to use the normal range for the serum T4 concentration multiplied by
1.5 in lieu of an automated free T4 assay.
The Free T4Index (FT4I)
Particularly useful in estimating the free T4 in severely ill patients is the
determination of the thyroid hormone–binding ratio (THBR), multiplying this
result by the total T4 (or T3) to obtain a free hormone index (FT4I or FT3I).  In
this test, a tracer quantity of labeled T4 (or T3) is added to serum, which is then
exposed to a solid phase matrix coated with T4 or T3 antibody or to an inert matrix
that binds the iodothyronine irreversibly. The proportion of labeled T4 or T3 bound
by the solid phase is then quantitated. This value, like the free fraction of T4
quantitated directly in a dialysate, varies inversely with the concentration of
unoccupied TBG sites in the serum. Where tracer T3 is used, its binding to TBG is
determined by the ratio of T4, not T3, to TBG in that T4 is present in 50- to 60-
fold higher concentrations than T3, has a much higher affinity for TBG than does
T3 and, therefore, determines the ratio of unoccupied to occupied TBG. The results
of such assays are normalized by comparing them with those obtained
simultaneously for standard control sera with normal TBG and serum T4
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concentrations. This is generally done by dividing the result for the unknown
sample by that obtained for control sera in the same assay. The quotient is the
THBR, which typically has a normal range of 0.85 to 1.10. Because the THBR is
proportional to the free fraction of the endogenous thyroid hormones in the serum,
it can be multiplied by the total T4 (or T3) concentration to estimate the free
thyroid hormone concentration, termed the free T3 or free T4 index (FT3I or FT4I)
Because the normal THBR is 1.0, the FT4I has a normal range in units that is
identical to that of the total T4 (or T3), for example, 64 to 142 for SI units and 5 to
11 in gravimetric terms.
Causes of a Suppressed TSH
The excess supply of thyroid hormone due to excessive exogenous thyroid
hormone or increased endogenous thyroid hormone production is the most
common cause of a reduction in the serum TSH. Patients Who present with clinical
symptoms usually have concentrations of TSH in serum below 0.1 mU/L. Such
patient’s serum have increased free T4. In rare patients with low iodine intake,
with clinical thyrotoxicosis, the FT4I is only high-normal despite a suppressed
TSH. An FT3I is required in those patients to establish a diagnosis of T3
thyrotoxicosis. When thyroid hormone supply is only slightly in excess of the
requirement for that patient, serum TSH is suppressed, but clinical manifestations
are subtle or absent and the FT4I (and FT3I) are in the high-normal range. Such
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minimal changes can occur with “euthyroid” Graves' disease, autonomous thyroid
hormone-producing adenomas, multinodular goiters, subacute or painless
thyroiditis, and the ingestion of an amount of exogenous thyroid hormone slightly
greater than that required for metabolic needs. This condition is termed subclinical
hyperthyroidism. After there is complete resolution of status of throtoxicosis there
will be suppression of the hypothalamic-pituitary axis for a period of 3 months [34]
[35]. The best test for assessing the physiologic state in such patients is the free T4
or FT4I. Because hCG can activate the TSH receptor, conditions in which hCG is
elevated, such as in the first trimester of pregnancy, with twin pregnancies, during
severe hyperemesis gravidarum, and in patients with hydatidiform mole or
choriocarcinoma, the TSH concentration is often suppressed. TSH returns to
normal in the second and third trimesters in the euthyroid patient. A persistently
suppressed TSH (<0.1 mU/L) in the pregnant patient after the first trimester
suggests that the hyperthyroidism is due to autonomous thyroid function.
Causes of an Elevated TSH
Usually in cases with an elevated TSH there will be a reduction T4 or T3 supply.
The most usual explanation is primary hypothyroidism. Also there is elevated TSH
in patients who are acutely ill like in renal insufficiency or the asynchrony in the
return of the thyroid and the hypothalamic-pituitary axes to normal as these
critically ill recover. The commonest aetiology for an elevated TSH worldwide is
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iodine deficiency. Patients with dysfunction of hypothalamic-pituitary axes have
low, normal, or increased serum TSH but they may have chemical and clinical
Hypothyroidism because the biologic effectiveness of the circulating TSH is
impaired due to abnormal glycosylation secondary to reduced TRH stimulation of
the thyrotrophs. With replacement of glucocorticoid TSH returns to normalcy
inspite of being previously elevated in cases of adrenal insufficiency. Despite the
utility and general efficacy of the serum TSH measurement alone as a screening
tool for identifying patients with thyroid dysfunction, a patient should not receive
treatment for this dysfunction solely on the basis of an abnormal TSH. The TSH
assay is an indirect reflection of thyroid hormone supply and does not, by itself,
permit a conclusive diagnosis of a specific disorder of thyroid hormone production.
Accordingly, the TSH abnormality must be verified and an alteration in thyroid
hormone concentrations verified before initiating treatment.
Tests That Assess the Metabolic Impact of Thyroid Hormones
Basal Metabolic Rate
Thyroid hormones increase energy expenditure and heat production, as manifested
by weight loss, increased caloric requirement, and heat intolerance. The normal
values when adjusted for gender and age is from -15% to +5% . In patients who are
severely hypothyroid it can be -40%, while in thyrotoxic patients it can be +25% to
+50%. Abnormal, usually elevated, values are seen during recovery in burn
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patients and in systemic disorders, such as febrile illnesses, pheochromocytoma,
myeloproliferative disorders, anxiety, and disorders associated with involuntary
muscular activity. Resting energy expenditure correlates very well with the free T4
and TSH in hypothyroid patients given varying doses of exogenous levothyroxine.
Biochemical Markers of Altered Thyroid Status
Occasionally lowdensity lipoprotein (LDL) cholesterol or markedly raised creatine
kinase MM isoenzyme can be seen in hypothyroidism. These tests are not useful in
the diagnosis of thyroid disease, but some, such as sex hormone–binding globulin
(SHBG), ferritin, or LDL cholesterol, have been used as end-points in clinical
studies of the responsivity of the liver to thyroid hormone in patients with thyroid
hormone resistance.
Serum Thyroglobulin
The sensitivity of modern thyroglobulin (Tg) assays is 1 ng/mL or even less. The
results can be artifactually altered by serum anti-Tg antibodies, and serum should
be screened for Tg antibodies with a sensitive Tg-antibody immunoassay or for
interferences with a recovery test. In immunoradiometric assays, interferences lead
to underestimations of Tg or false-negative values with radioimmunoassays
relatively unaffected especially if the antibody titer is low. Mean normal values
usually vary with the type of assay used but they are in the range of 30 pmol/L (20
ng/mL). Concentrations are somewhat higher in women than in men and are
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several fold elevated in pregnant women and in the newborn.  Levels are elevated
in three types of thyroid disorders: goiter and thyroid hyper function, inflammatory
or physical injury to the thyroid, and differentiated follicular cell derived thyroid
tumors. Transient elevations occur in patients with subacute thyroiditis and as a
result of trauma to the gland during thyroid surgery or after I131 therapy.
Subnormal or undetectable concentrations are found in patients with thyrotoxicosis
factitia and aid in differentiating this disorder from other causes of thyrotoxicosis
with a low thyroid radioiodine uptake (RAIU). Antithyroglobulin antibodies
interfere with measurements of the Tg concentration precluding its use in patients
with Hashimoto's disease. A major clinical value of measuring the level of serum
Tg is in the management, but not in the diagnosis, of differentiated thyroid
carcinoma. Serum Tg concentrations are increased in patients with both benign and
differentiated malignant follicular-cell derived tumors of the thyroid and do not
serve to distinguish between the two. After total thyroid ablation for papillary or
follicular thyroid carcinoma, Tg should not be detectable, and its subsequent
appearance signifies the presence of persistent or recurrent disease. Secretion of Tg
is TSH-dependent. In the hypothyroid newborn, serum Tg is undetectable in
patients with thyroid agenesis and is usually elevated in those with ectopic thyroid
tissue or goiter.
31
Tests for Thyroid Autoantibodies
Autoantibodies to Thyroid Peroxidase and Thyroglobulin
Modern assay techniques for thyroid autoantibodies have good precision because
they depend on the direct measurement of the interaction between autoantibody
and autoantigen (i.e., the interaction between labelled thyroid antigen and the
patient's serum). In general, the more sensitive an assay, the more precise and
antigen-specific it is. However, many euthyroid individuals in our population
exhibit low levels of autoantibodies and, therefore, the specificity of the more
sensitive tests is reduced and the absolute concentration becomes more important;
the higher the concentration of autoantibody, the greater the clinical
specificityAntibodies to thyroglobulin (Tg) and thyroid peroxidase (TPO) are
found in almost 100 % of patients with Hashimoto's disease which is otherwise
called autoimmune thyroiditis and in 50% to 90% of cases of grave’s disease.
Antibodies directed against the TSH receptor is also found in grave’s disease.
Although the presence of such autoantibodies favors a diagnosis of an autoimmune
cause for the hyperthyroidism over other causes, the tests are neither sensitive nor
specific in this setting and are interpretable only as part of the clinical scenario.
TSH receptor antibodies remain the test of choice in such patients.
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Thyroid Autoantibodies in Nonautoimmune Thyroid Disorders
Persons with isolated thyroid nodules and cancer, multinodular goiter, sporadic
goiter and insulin-dependent diabetes mellitus (IDDM) also have antibodies to Tg
and TPO.
Radioiodine Uptake
The only direct test of thyroid function employs a radioactive isotope of iodine as a
tag for the body's stable form of iodine, I 127. Measurements of  RAIU are usually
done at 24 hours. It indicates the rate at which thyroid hormone is synthesized and
the rate at which it is released into the blood.
The perchlorate discharge test
In normal individuals, more than 90% of thyroidal radioiodine is present as
iodotyrosine and iodothyronine within minutes of its entry into the thyroid. It is
then no longer in the intracellular iodide pool. In patients with Pendred's syndrome
or with other disorders that inhibit the iodination of tyrosine, such as Hashimoto's
thyroiditis, or those receiving thiourea drugs, this process is delayed, as shown by
the exit (discharge) of more than 10% of the thyroidal radioiodine within 2 hours
of administration of 500 mg of KClO4. Perchlorate inhibits NIS function by
competing with iodide for NIS, eliminating the iodide gradient that is required for
maintaining the radioiodide in the gland. This illustrates that both iodide transport
33
by NIS at the basal pole of the thyrocyte and its efflux across the apical membrane
by pendrin are required for thyroid hormone synthesis.
States Associated with Increased RAIU
Hyperthyroidism
Hyperthyroidism causes increased RAIU unless body iodide stores are increased.
Such increases in uptake are always evident except in patients with severe
thyrotoxicosis, in whom release of hormone can be so rapid that the thyroid
content of I* has decreased to the normal range by the time the measurement is
made. This condition is rare and is usually associated with obvious thyrotoxicosis.
Aberrant hormone synthesis
RAIU can be increased in the absence of hyperthyroidism in disorders in which
iodine accumulation is normal but the secretion of hormone is impaired, such as in
patients with abnormal thyroglobulin synthesis.The magnitude of the increase in
uptake and the time at which the plateau is achieved vary with the nature and
severity of the disorder. Differentiation of the foregoing states from
hyperthyroidism is generally not difficult, because in the former, clinical findings
and laboratory evidence of hyperthyroidism are lacking, and indeed
hypothyroidism may be present.
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Iodine deficiency
RAIU is increased in acute or chronic iodine deficiency, as demonstrated by
measurement of urinary iodine excretion, with urinary iodine values lower than
100 ?g/day, indicating deficiency. Chronic iodine deficiency is usually the result of
an inadequate content of iodine in the food and water (endemic iodine deficiency).
Patients with cardiac, renal, or hepatic disease may develop iodine deficiency if
given diets severely restricted in salt, especially if diuretic agents are administered.
Response to thyroid hormone depletion
Rebound increases in RAIU are seen after withdrawal of antithyroid therapy, after
subsidence of transient or subacute thyroiditis, and after recovery from prolonged
suppression of thyroid function by exogenous hormone. A striking increase in
uptake occurs in patients with iodide-induced myxedema after cessation of iodide
administration. The duration of the rebound depends on the time required to
replenish thyroid hormone stores.
Excessive hormone loses
In nephrotic syndrome, excessive losses of hormone in the urine occurring in
association with urinary loss of binding protein cause a compensatory increase in
hormone synthesis and RAIU. A similar sequence may occur when losses of
hormone via the gastrointestinal tract are abnormal, as in chronic diarrheal states or
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during ingestion of agents, such as soybean protein and cholestyramine, that bind
T4 in the gut.
States Associated with Decreased RAIU
Exogenous thyroid hormone : Thyrotoxicosis factitia
Except in disorders in which homeostatic control is disrupted or overridden (e.g.,
Graves' disease or autonomously functioning thyroid nodules), administration of
exogenous thyroid hormone suppresses TSH secretion and reduces the RAIU,
usually to values below 5%. Low values of the RAIU in a patient who is clinically
thyrotoxic may also indicate the presence of Thyrotoxicosis factitia, the syndrome
produced by the ingestion of excess thyroid hormone. The unmeasurably low level
of Tg in serum differentiates thyrotoxicosis factitia from other causes of
thyrotoxicosis with decreased RAIU.
Disorders of thyroid hormone storage
The RAIU is usually low in the early phase of subacute thyroiditis and in chronic
thyroiditis with transient hyperthyroidism. Here, inflammatory follicular disruption
leads to loss of the normal storage function of the gland and leakage of hormone
into the blood. In the early stage of subacute thyroiditis, leakage of hormone is
usually sufficient to suppress TSH secretion and the RAIU. Transient
hypothyroidism often occurs late in both diseases, when stores of preformed
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hormone are depleted; the RAIU may return to normal or increased values at that
time.
Exposure to excessive iodine
Common offenders are organic iodinated dyes used as x-ray contrast media and
amiodarone. The duration of suppression of the uptake varies among individuals
and with the compound administered. In general, dyes used for pyelography or CT
scanning are cleared within a few months, whereas amiodarone may influence the
uptake for up to 12 months due to its storage in fat. A single large dose of
inorganic iodide can decrease uptake for several days, and chronic ingestion of
iodide may depress the uptake for many weeks. Excessive quantities of iodine may
also be present in vitamin and mineral preparations, vaginal or rectal suppositories,
and iodinated antiseptics such as povidone. The measurement of urinary iodine
excretion is an invaluable means of establishing or excluding the existence of
excessive body iodide stores; the 24-hour iodine excretion can be extrapolated
from the iodide-to-creatinine ratio in a random urine sample. Values in excess of 2
mg/day can account for a low RAIU value.
Thyroid Ultrasound
Ultrasonography is used increasingly to assist in the diagnosis of nodular thyroid
disease, a reflection of the limitations of the physical examination and
improvements in ultrasound technology. Using 10-MHz instruments, spatial
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resolution and image quality are excellent, allowing the detection of nodules and
cysts >3 mm. In addition to detecting thyroid nodules, ultrasound is useful for
monitoring nodule size and for the aspiration of nodules or cystic lesions.
Ultrasound-guided FNA biopsy of thyroid lesions lowers the rate of inadequate
sampling. Ultrasonography is also used in the evaluation of recurrent thyroid
cancer, including possible spread to cervical lymph nodes.
HYPOTHYROIDISM[26]
CAUSES OF HYPOTHYROIDISM
Primary
Autoimmune hypothyroidism: Hashimoto's thyroiditis, atrophic thyroiditis
Iatrogenic: 131I treatment, subtotal or total thyroidectomy, external irradiation of
neck for lymphoma or cancer
Drugs: iodine excess (including iodine-containing contrast media and amiodarone),
lithium, antithyroid drugs, p-aminosalicylic acid, interferon- and other cytokines,
aminoglutethimide, sunitinib
Congenital hypothyroidism: absent or ectopic thyroid gland, dyshormonogenesis,
TSH-R mutation
Iodine deficiency
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Infiltrative disorders: amyloidosis, sarcoidosis, hemochromatosis, scleroderma,
cystinosis, Riedel's thyroiditis
 Overexpression of type 3 deoiodinase in infantile hemangioma
Transient
Silent thyroiditis, including postpartum thyroiditis
Subacute thyroiditis
Withdrawal of thyroxine treatment in individuals with an intact thyroid
After 131I treatment or subtotal thyroidectomy for Graves' disease
Secondary
 Hypopituitarism: tumors, pituitary surgery or irradiation, infiltrative disorders,
Sheehan's syndrome, trauma, genetic forms of combined pituitary hormone
deficiencies
Isolated TSH deficiency or inactivity
Bexarotene treatment
Hypothalamic disease: tumors, trauma, infiltrative disorders, idiopathic
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Congenital Hypothyroidism
PREVALANCE
Hypothyroidism occurs in about 1 in 4000 newborns. It may be transient,
especially if the mother has TSH-R blocking antibodies or has received antithyroid
drugs, but permanent hypothyroidism occurs in the majority. Neonatal
hypothyroidism is due to thyroid gland dysgenesis in 80–85%, to inborn errors of
thyroid hormone synthesis in 10–15%, and is TSH-R antibody-mediated in 5% of
affected newborns. The developmental abnormalities are twice as common in girls.
Mutations that cause congenital hypothyroidism are being increasingly identified,
but the vast majority remain idiopathic.
CLINICAL MANIFESTATIONS
The baby presents with features such an increased duration of jaundice, do not feed
properly, reduction in tone of muscles, big tongue, also the presence of hernias of
umbilicus. Symptoms include tiredness, weakness, dry skin, feeling cold, hair loss,
 difficulty concentrating and poor memory, constipation, weight gain with poor
appetite, dyspnea, hoarse voice, menorrhagia (later oligomenorrhea or
amenorrhea), paresthesia, impaired hearing. Signs include dry coarse skin; cool
peripheral extremities, puffy face, hands, and feet (myxedema), diffuse alopecia,
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bradycardia, peripheral edema, delayed tendon reflex relaxation, carpal tunnel
syndrome, serous cavity effusions.
DIAGNOSIS AND TREATMENT
Because of the severe neurologic consequences of untreated congenital
hypothyroidism, neonatal screening programs have been established. Diagnosis
based on measurement of TSH or T4 levels in heel-prick blood specimens. When
the diagnosis is confirmed, T4 is instituted at a dose of 10–15 g/kg per day, and the
dose is adjusted by close monitoring of TSH levels. T4 requirements are relatively
great during the first year of life, and a high circulating T4 level is usually needed
to normalize TSH. Early treatment with T4 results in normal IQ levels, but subtle
neurodevelopmental abnormalities may occur in those with the most severe
hypothyroidism at diagnosis or when treatment is delayed or suboptimal.
Autoimmune Hypothyroidism
CLASSIFICATION
Hashimoto's or goitrous thyroiditis, atrophic thyroiditis. In this disease there will
be a period in which increase in thyroid stimulating hormone maintains a normal
quantity of T3 and T4. Though some may have minor symptoms, this state is said
as subclinical hypothyroidism. Further in the course the quantity of free T4
becomes less while that of thyroid stimulating hormone increases still more and the
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patient starts having more symptoms related to thyroid hormone deficiency (mostly
thyroid stimulating hormone greater than 10 mIU/ litre). This is called to be
clinical hypothyroidism.
PREVALANCE
The mean annual incidence rate of autoimmune hypothyroidism is up to 4 per 1000
women and 1 per 1000 men. It is more prevalent among some people in countries
like japan, probably due to reasons related to genetics and increased long term
consumption of foods rich in iodine. The mean age at diagnosis is 60 years, and
there is an increase in prevalence of cases of clinical hypothyroidism as the age
advances. Subclinical hypothyroidism is found in 6–8% of women (10% over the
age of 60) and 3% of men. The annual risk of developing clinical hypothyroidism
is about 4% when subclinical hypothyroidism is associated with positive TPO
antibodies.
PATHOGENESIS
In Hashimoto's, it is characterized by an increased invasion of the gland by
lymphocytes and also there will be presence of germinal center, the follicles
decrease in size, metaplasia of oxyphil cells, will be no colloid, and presence of
fibrosis of the gland. The disease like atrophic thyroiditis is characterized by still
more increased increased fibrosis while the invasion by the lymphocyte cells is not
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much as seen in case of hashimoto’s , also the follicles present in the gland are
decreased to almost total absence. This disease probably denotes the hashimoto’s
in it’s last stage instead of a separate disease. Subjects are more prone to this
disease called autoimmune hypothyroidism characterized by many kinds of factors
relating to genes, environment, and in siblings they are more prone to develop
grave’s disease which is also known as autoimmune hypothyroidism. Human
leukocyte antigen- DR polymorphisms like of DR 3,4,5 are seen among
Europeans. There is a gene which plays a role in the regulation of T lymphocyte
called CTLA-4 which has got polymorphisms in it. These two associations seen
among the genes are also seen in other diseases caused by autoimmunity which
teaches us the link seen with autoimmune hypothyroidism to diseases related to
autoimmunity such as type one diabetes, disease of adrenals like addison’s, anemia
of the pernicious type and other diseases of the skin like vitiligo. The above two
autoimmune mechanisms discussed are the reason for nearly 50% of the factors
related to genes in a case of autoimmune hypothyroidism. Similar other genetic
loci are yet to be found out. Down syndrome is linked with the above disease ,
autoimmune hypothyroidism because one of the gene present on chromosome
twenty one plays a role in it. The effect caused by the sex steroid on the way in
which the immunity of the person responds is probably the reason why the
autoimmunity of the gland is seen more among women however one of the factors
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in regards to the genes which is in fact associated with the chromosome X, the
reason why lot of cases of autoimmune hypothyroidism is encountered in diseases
like the turner’s. The factors related to the environment which play a role in the
development of the disease are not known much at this point of time. An increased
consumption of iodine may play a role in the development of the disease we are
discussing that is autoimmune hypothyroidism due to direct toxic effects on the
gland or by other mechanisms related to immune response. With regards to
infectious cause for autoimmune hypothyroidism we have not got much evidence
except rubella syndrome which is acquired congenitally. The thyroiditis caused by
infectious cause like virus do not play a role in the manifestation of the disease in
discussion autoimmune hypothyroidism. The thyroid lymphocytic infiltrate in
autoimmune hypothyroidism is composed of cells such as CD4+ and also cells like
CD8+ which are in the activated state while also having B lymphocytes. The cells
in the thyroid gland gets destroyed by cells like the CD8+, which destroy their
targets by either perforin-induced cell necrosis or granzyme B–induced apoptosis.
In addition, local T cell production of cytokines, such as tumor necrosis factor
(TNF), IL-1, and interferon (IFN-gamma), may render thyroid cells more
susceptible to apoptosis mediated by death receptors, such as Fas, which are
activated by their respective ligands on T cells. The functioning of the cells of the
thyroid gland are impaired by the action of the above cytokines and the cytokines
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increase the molecules which induce inflammation through their increased
expression by the cells of the thyroid gland and these molecules are other
cytokines, human leukocyte antigen class one and two molecules, nitric oxide.
Administration of high concentrations of cytokines for therapeutic purposes
(especially IFN-gamma) is associated with increased autoimmune thyroid disease,
possibly through mechanisms similar to those in sporadic disease. Antibodies to
TPO and Tg are clinically useful markers of thyroid autoimmunity, but any
pathogenic effect is restricted to a secondary role in amplifying an ongoing
autoimmune response. TPO antibodies fix complement, and complement
membrane-attack complexes are present in the thyroid in autoimmune
hypothyroidism. However, the journey of thyroglobulin or the thyroid peroxidase
antibodies through the placenta does not have any effect on the thyroid gland of the
fetus which gives a clue that injury due to T lymphocyte cell is needed to destroy
the gland. Up to 20% of patients with autoimmune hypothyroidism have antibodies
against the TSH-R, which, in contrast to TSI, do not stimulate the receptor but
prevent the binding of TSH. These TSH-R-blocking antibodies, therefore, cause
hypothyroidism and, especially in Asian patients, thyroid atrophy. Their
transplacental passage may induce transient neonatal hypothyroidism. Rarely,
patients have a mixture of TSI and TSH-R-blocking antibodies, and the function of
the gland fluctuates between hyper functioning and hypo functioning depending
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upon which antibody plays a major role at that moment. It is very tough to say in
which route the disease will progress in those people and need a close watch on the
functioning of the gland. Various bioassays are in vogue to say that TSH-R-
blocking antibodies reduce the cyclic AMP–inducing effect of TSH on cultured
TSH-R-expressing cells, but these assays are difficult to perform. Assays like TBII
which quantify how much antibodies bind with the receptor by competing with
radio labeled thyroid stimulating hormone cannot separate TSI- and TSH-R-
blocking antibodies, but if the outcome is positive in the subject it points out that
blocking antibodies exist. These assays does not generally alter clinical
management, although it may be useful to confirm the cause of transient neonatal
hypothyroidism.
CLINICAL MANIFESTATIONS
Patients with Hashimoto's thyroiditis may present because of goiter rather than
symptoms of hypothyroidism. Patients with atrophic thyroiditis or the late stage of
Hashimoto's thyroiditis present with symptoms and signs of hypothyroidism. The
skin is dry, and there is decreased sweating, thinning of the epidermis, and
hyperkeratosis of the stratum corneum. skin thickening without pitting
(myxedema). Typical features include a puffy face with edematous eyelids and
nonpitting pretibial edema. There is pallor, often with a yellow tinge to the skin.
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Nail growth is retarded, and hair is dry, brittle, difficult to manage, and falls out
easily and there is thinning of the outer third of the eyebrows, although this is not a
specific sign of hypothyroidism. Other common features include constipation and
weight gain (despite a poor appetite). Libido is decreased in both sexes, and there
may be oligomenorrhea or amenorrhea in long-standing disease, but menorrhagia
is also common. Fertility is reduced, and the incidence of miscarriage is increased
and galactorrhea. Myocardial contractility and pulse rate are reduced, leading to a
reduced stroke volume and bradycardia. Increased peripheral resistance may be
accompanied by hypertension, particularly diastolic and there is cool extremities.
Pericardial effusions, conductive deafness, dyspnea may be caused by pleural
effusion, impaired respiratory muscle function, diminished ventilatory drive, or
sleep apnea. Carpal tunnel and other entrapment syndromes are common, as is
impairment of muscle function with stiffness, cramps, and pain. On examination,
there may be slow relaxation of tendon reflexes and pseudomyotonia. Memory and
concentration are impaired. Experimentally, PET scans examining glucose
metabolism in hypothyroid subjects show lower regional activity in the amygdala,
hippocampus, and perigenual anterior cingulated cortex, among other regions, and
this activity corrects after thyroxine replacement. Rare neurologic problems
include reversible cerebellar ataxia, dementia, psychosis, and myxedema coma.
Hashimoto’s encephalopathy has been defined as a steroid-responsive syndrome
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associated with TPO antibodies, myoclonus, and slow-wave activity on
electroencephalography, but the relationship with thyroid autoimmunity or
hypothyroidism is not established. The hoarse voice and occasionally clumsy
speech of hypothyroidism reflect fluid accumulation in the vocal cords and tongue.
The features described above are the consequence of thyroid hormone deficiency.
However, autoimmune hypothyroidism may be associated with signs or symptoms
of other autoimmune diseases, particularly vitiligo, pernicious anemia, Addison's
disease, alopecia areata, and type 1 diabetes mellitus. Less-common associations
include celiac disease, dermatitis herpetiformis, chronic active hepatitis,
rheumatoid arthritis, systemic lupus erythematosus (SLE), myasthenia gravis, and
Sjögren's syndrome. Thyroid-associated ophthalmopathy, occurs in about 5% of
patients with autoimmune hypothyroidism. Autoimmune hypothyroidism is
uncommon in children and usually presents with slow growth and delayed facial
maturation. The appearance of permanent teeth is also delayed. Myopathy, with
muscle swelling, is more common in children than in adults. In most cases, puberty
is delayed, but precocious puberty sometimes occurs. There may be intellectual
impairment if the onset is before 3 years and the hormone deficiency is severe.
LABORATORY EVALUATION
A normal TSH level excludes primary (but not secondary) hypothyroidism. If the
TSH is elevated, an unbound T4 level is needed to confirm the presence of clinical
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hypothyroidism. Once subclinical hypothyroidism otherwise the existence of
clinically manifested hypothyroidism is found out the cause for the disease is
found out by showing the existence of antibodies to the thyroid perroxidase, which
are present in >90% of patients with autoimmune hypothyroidism. If the reason for
the aetiology of the existence of the goiter when present along with
hypothyroidism, fine needle aspiration biopsy clinches the diagnosis that is
autoimmune thyroiditis. Also there will be some changes seen in hypothyroidism
such as more creatine phosphokinase, hypercholesterolemia, hypertriglyceridemia,
and decreased haemoglobin presenting as anemia.
Treatment: Hypothyroidism
If there is no residual thyroid function, the daily replacement dose of levothyroxine
is usually 1.6 ?g/kg body weight (typically 100–150 ?g). In many patients,
however, lower doses suffice until residual thyroid tissue is destroyed. In patients
who develop hypothyroidism after the treatment of Graves' disease, there is often
underlying autonomous function, necessitating lower replacement doses (typically
75–125 ? g/d). Adult patients under 60 without evidence of heart disease may be
started on 50–100 ? g levothyroxine (T4) daily. The dose is adjusted on the basis
of TSH levels, with the goal of treatment being a normal TSH, ideally in the lower
half of the reference range. TSH responses are gradual and should be measured
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about two months after beginning treatment otherwise when there is any alteration
made to the dose in which the hormone is given. The clinical effects of
levothyroxine replacement are slow to appear. Patients may not experience full
relief from symptoms until 3–6 months after normal TSH levels are restored. The
dose of the hormone is adjusted by increasing about 12.5 or 25 microgram if the
thyroid stimulating hormone is having high values and decreases in dosage should
be made in the same quantity if the thyroid stimulating hormone is having low
values. Subjects with a less value of thyroid stimulating hormone due to any
aetiology which includes overtreatment with the hormone are prone to develop
cardiac problems like atrial fibrillation, decreased density of the bone.  Although
dessicated animal thyroid preparations (thyroid extract USP) are available, they are
not recommended because the ratio of T3 to T4 is nonphysiologic. The use of
levothyroxine combined with liothyronine (triiodothyronine, T3) has been
investigated, but benefit has not been confirmed in prospective studies. There is no
place for liothyronine alone as long-term replacement, because the short half-life
necessitates three or four daily doses and is associated with fluctuating T3 levels.
Once full replacement is achieved and TSH levels are stable, follow-up
measurement of TSH is recommended at annual intervals and may be extended to
every 2–3 years if a normal TSH is maintained over several years. It is important to
ensure ongoing adherence, however, as patients do not feel any symptomatic
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difference after missing a few doses of levothyroxine, and this sometimes leads to
self-discontinuation. In patients of normal body weight who are taking 200 ? g of
levothyroxine per day, an elevated TSH level is often a sign of poor adherence to
treatment. This is also the likely explanation for fluctuating TSH levels, despite a
constant levothyroxine dosage. Such patients often have normal or high unbound
T4 levels, despite an elevated TSH, because they remember to take medication for
a few days before testing; this is sufficient to normalize T4, but not TSH levels. It is
important to consider variable adherence, because this pattern of thyroid function
tests is otherwise suggestive of disorders associated with inappropriate TSH
secretion. Because T4 has a long half-life (7 days), patients who miss a dose can be
advised to take two doses of the skipped tablets at once. Other causes of increased
levothyroxine requirements must be excluded, particularly malabsorption (e.g.,
celiac disease, small-bowel surgery), estrogen therapy, and drugs that interfere
with T4 absorption or clearance such as cholestyramine, ferrous sulfate, calcium
supplements, lovastatin, aluminum hydroxide, rifampicin, amiodarone,
carbamazepine, and phenytoin. For subclinical hypothyroidism the most recent
guidelines do not recommend treatment if TSH levels are below 10 mIU/L. It is
important to confirm any elevation of TSH is sustained for 3 months before
treatment is given.
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SPECIAL TREATMENT CONSIDERATIONS
Rarely, levothyroxine replacement is associated with pseudotumor cerebri in
children. Presentation appears to be idiosyncratic and occurs months after
treatment has begun. Women with a history or high risk of hypothyroidism should
ensure that they are euthyroid prior to conception and during early pregnancy as
maternal hypothyroidism may adversely affect fetal neural development and cause
preterm delivery. The presence of thyroid autoantibodies alone, in a euthyroid
patient, is also associated with preterm delivery, and outcome may be improved by
levothyroxine treatment. Thyroid function should be evaluated immediately after
pregnancy is confirmed and at the beginning of the second and third trimesters.
The dose of levothyroxine may need to be increased by 50% during pregnancy and
returned to previous levels after delivery. Elderly patients may require 20% less
thyroxine than younger patients. In the elderly, especially patients with known
coronary artery disease, the starting dose of levothyroxine is 12.5–25 ?g/d with
similar increments every 2–3 months until TSH is normalized. In some patients, it
may be impossible to achieve full replacement despite optimal antianginal
treatment. Emergency surgery is generally safe in patients with untreated
hypothyroidism, although routine surgery in a hypothyroid patient should be
deferred until euthyroidism is achieved. Myxedema coma still has a high mortality
rate, despite intensive treatment. Clinical manifestations include reduced level of
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consciousness, sometimes associated with seizures, as well as the other features of
hypothyroidism. Hypothermia can reach 23°C (74°F). There may be a history of
treated hypothyroidism with poor compliance, or the patient may be previously
undiagnosed. Myxedema coma almost always occurs in the elderly and is usually
precipitated by factors that impair respiration, such as drugs (especially sedatives,
anesthetics, antidepressants), pneumonia, congestive heart failure, myocardial
infarction, gastrointestinal bleeding, or cerebrovascular accidents. Sepsis should
also be suspected. Exposure to cold may also be a risk factor. Hypoventilation,
leading to hypoxia and hypercapnia, plays a major role in pathogenesis;
hypoglycemia and dilutional hyponatremia also contribute to the development of
myxedema coma. Levothyroxine can initially be administered as a single IV bolus
of 500 ?g, which serves as a loading dose. Although further levothyroxine is not
strictly necessary for several days, it is usually continued at a dose of 50–100 ?g/d.
If suitable IV preparation is not available, the same initial dose of levothyroxine
can be given by nasogastric tube (though absorption may be impaired in
myxedema). An alternative is to give liothyronine (T3) intravenously or via
nasogastric tube, in doses ranging from 10 to 25 ?g every 8–12 h. Another option
is to combine levothyroxine (200 ?g) and liothyronine (25 ?g) as a single, initial
IV bolus followed by daily treatment with levothyroxine (50–100 ?g/d) and
liothyronine (10 ?g every 8 h). External warming is indicated only if the
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temperature is <30°C. Parenteral hydrocortisone (50 mg every 6 h) should be
administered. Any precipitating factors should be treated, including the early use of
broad-spectrum antibiotics, pending the exclusion of infection. Ventilatory support
with regular blood gas analysis is usually needed during the first 48 hours.
Hypertonic saline or IV glucose may be needed if there is severe hyponatremia or
hypoglycemia. Hypotonic IV fluids should be avoided because they may
exacerbate water retention secondary to reduced renal perfusion and inappropriate
vasopressin secretion. The metabolism of most medications is impaired, and
Sedatives should be avoided if possible or used in reduced doses. Medication blood
levels should be monitored, when available, to guide dosage.
SUBCLINICAL HYPOTHYROIDISM
The term subclinical hypothyroidism was originally used to describe the patient
with a low-normal free T4 but a slightly elevated serum TSH level. Other terms for
this condition are mild hypothyroidism early thyroid failure, preclinical
hypothyroidism, and decreased thyroid reserve. The TSH elevation in such patients
is modest, with values typically between 4 and 15 mU/L, although patients with a
TSH above 10 mU/L more often have a reduced free T4 and may have some
hypothyroid symptoms.
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PREVALENCE AND NATURAL HISTORY
Hypothyroidism is much higher in females than males and more cases are seen as
age advances. The overall prevalence has been reported to range from 4–10% in
large general population screening surveys[36-40] and from 7–26% in studies of the
elderly[36-38], [21,24,41-44]. Subclinical hypothyroidism is a condition which is usually
seen  in  patients  before  they  develop  the  full  clinical  picture  with  the  classic
symptoms of hypothyroidism thereby becoming patients with clinical
hypothyroidism. It has been found out from some studies that about 3 to 18% of
people who were diagnosed as subclinical hypothyroidism ultimately converted
into patients of hypothyroidism with low free T3 and low free T4 with elevated
TSH who were followed for a period of one year [43] [44], [45-50].There is evidence
from a study conducted by some researchers regarding how subclinical
hypothyroidism evolves naturally in about 154 women with the disease who were
followed for a period of ten years and it was found out that about 57% with the
disease still had it while 34% developed full blown hypothyroidism and 9% had
their TSH values return to normalcy. The strongest predictors of progression are
the following determinants like patients who had antibodies against the thyroid, the
quantity of TSH more than twenty microunits per milliliter of serum, in the past
had their thyroid shrunken with radioiodine in those with graves disease, radiation
treatment for cancers not relating to thyroid and finally those on lithium treatment
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[43-49]. One Prevalence Study [37] which was done in Colorado in which the
researchers found out the TSH values in the serum and also recorded the symptoms
experienced by about 25,000 people. In this study it was found out that 9.5% of
them had TSH above the normal range and the interesting fact is that 8.9% of the
people who turned out with their TSH above normal range did not receive any
replacement with thyroid hormone; also the TSH value in 75% people was
between five and ten micro units per milliliter of serum.
Effects on serum lipid levels
Several cross sectional studies show that serum cholesterol levels are elevated in
individuals with mild thyroid failure when compared with euthyroid controls [38].
One of the studies done in Colorado pointed out the fact that total cholesterol’s
value of euthyroid subject’s mean was two hundred and sixteen mg/dL and two
hundred and twenty four mg/dL in subjects with SH[37]. Many studies done showed
that there is a decrease in LDL cholesterol in those treated with levothyroxine. But
the majority of these researches showing advantage of treatment is not for those
subjects with thyroid stimulating hormone in the serum between five and ten
mIU/L. It was shown in the meta analysis conducted with thirteen studies that the
cholesterol levels showed an improvement with treatment[51]. But it was found out
that in one of the reviews conducted in the year 2004 the data were not found to be
enough to prove advantage of levothyroxine treatment with relation to the
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cholesterol levels[40].This shows that the cholesterol values in the subject will
decrease with hormone treatment if they have the thyroid stimulating hormone in
the serum more than ten mIU/L and doubtful if the thyroid stimulating hormone
value is below ten mIU/L.
CARDIAC EFFECTS
Studies have shown slowed left ventricular relaxation time, increased vascular tone
at rest, and left ventricular systolic dysfunction with exercise and impaired
endothelial function [52]. Some studies have shown improvement of cardiac
contractibility and systolic time interval with levothyroxine therapy [52]. Rotterdam
Study pointed out that subclinical hypothyroidism is linked to myocardial
infarction also to another cardiac disease like the calcific disease of the aortic valve
[24]. Also multiple meta analyses has been done about observational studies and
researchers have found a link with subclinical hypothyroidism and ischemic heart
disease[53-55].
SOMATIC AND NEUROMUSCULAR EFFECTS
Patients with subclinical hypothyroidism have symptoms like dry skin, poor
memory, slow thinking, muscle weakness, fatigue, muscle cramps, cold
intolerance, puffy eyes, constipation, and hoarseness. Findings like improper
functioning of peripheral nerves characterized by reduced amplitude[56] and
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reflexes like the stapedial having some problems [57] been found. Also problems
like increase in the creatine phosphokinase[58] , activities like excess physical
exertion causes a rise in lactate[59] , and furthermore findings like repeated
discharges are seen in investigations like surface electromyography [60]
TREATMENT
Risk and benefits of treatment
There are studies which have evaluated the advantages of treatment of subclinical
hypothyroidism and it has been found that treating the condition causes a
favourable change in the lipid status, some symptoms associated with the disease
are cleared and to add to the advantage it stalls the patient from ending up in gross
hypothyroidism[3]. Quite a few researches have also found out some perks due to
treatment like a decrease in the LDL and the total amount of cholesterol in those
patients treated with l-T4 hormone [61,62]. But it has also been found out that
treating aged patients with this hormone gives some problems like increase in the
thyroid hormone levels in blood thereby causing cardiac problems fibrillation of
the atrium and also bone weakening due to decrease in bone cells. However the
benefits of improvement in the cholesterol levels is not seen in those subjects who
presented with values of TSH below 10 mU/liter [61,63,64].
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Subclinical hypothyroidism with serum thyroid stimulating hormone between
5.1 and 10 mU/L
There are no studies which have been done on a huge scale with randomization to
show a definite bringing down of cholesterol due to levothyroxine treatment in this
group of patients. One of the studies done in this subgroup of patients with thyroid
stimulating hormone failed to bring out any reduction in cholesterol[65]. Therefore
before starting treatment with levothyroxine in this subgroup doctors should first
individualize the patient and many factors like pregnancy or intention of
pregnancy, goiter, therapeutic trial for possible hypothyroid symptoms, patient
preference, childhood and adolescence, 2 TSH levels >8 mIU/L, bipolar disorder,
depression, infertility, presence of antithyroid antibodies, progressive TSH
increase, ovulatory dysfunction, young age, hyperlipidemia?
Subclinical hypothyroidism with thyroid stimulating hormone in the serum
above 10 mU/L
Most endocrinologists say that everyone with subclinical hypothyroidism and
having thyroid stimulating hormone in the serum in excess of 10 mIU/L should
commence their treatment with the hormone that is levothyroxine[66,67].  There  is
quite a few data showing the harmful effects of subclinical hypothyroidism in this
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category of patients. Various studies depicted that hormone treatment have brought
about an eight milligram decrease in LDL values[51,68].
Subclinical hypothyroidism during pregnancy
Woman who are pregnant and those planning to get pregnant presenting with
subclinical hypothyroidism should be treated with levothyroxine so that TSH is
brought again in the normal range. This is because high TSH causes increased fetal
wastage or neuropsychological complications in the offspring. Although there are
no published intervention trials assessing the benefits of thyroid hormone
replacement in this special population, the potential benefit-risk ratio of
levothyroxine therapy justifies its use. The dose of levothyroxine required during
pregnancy increases and so the concentration of serum TSH should be seen every 6
to 8 weeks and the dose adjusted. The risks associated with the appropriate
management of levothyroxine therapy are minimal.
Subclinical hypothyroidism in treated overt hypothyroid individuals
When subclinical hypothyroidism is noted in levothyroxine treated patients with
overt hypothyroidism, the dosage of levothyroxine should be adjusted to bring
serum TSH into reference range. Whether the target TSH level should be in the
lower half of reference range is controversial because there are no data
demonstrating improved clinical outcomes with this strategy. Nevertheless, when
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serum TSH is in the upper half of reference range and levothyroxine treated
patients continue to note symptoms suggestive of hypothyroidism, it is reasonable
to increase levothyroxine dosage to bring serum TSH into lower portion of
reference range. The rapidity of dosage adjustment depends on patient’s age and
medical co morbidities. Minimal TSH elevations may not require dosage
adjustment in patients who feel well, particularly those with arrhythmias or other
cardiac disorders.
THYROXINE THERAPY
The treatment with levothyroxine be given to all people with subclinical
hypothyroidism and having thyroid stimulating hormone in the serum more than 10
mIU/L , also for people having thyroid stimulating hormone in the serum between
5.1 and 10 mIU/L the decision for treatment is done on an individual patient basis.
Mostly treatment is started with minimal doses of levothyroxine in the range of 50
to 75 ?g [69]. Since many patients ultimately land up in hypothyroidism few doctors
prescribe a full dose weighing on the benefits of treatment. But it is recommended
to begin the treatment for these patients with 25 to 75 ?g daily taking in to
consideration various factors like the subject’s age, the quantity of free thyroxine
and the quantity of serum thyroid stimulating hormone in the subject. After a
period of eight weeks the level of thyroid stimulating hormone in the serum should
be found out and there be adjustment made to the dosage. On getting a normal
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thyroid stimulating hormone level in the serum the hormone level can be seen after
a period of six months and after that once a year. In patients who are young the
target for maintaining the level of thyroid stimulating hormone in the serum should
be between 0.3 and 3 mIU/L. While for patients who are of elderly category the
range  can  be  placed  higher.  In  an  effort  to  reduce  the  TSH  level  in  serum  by
prescribing the hormone we should also have an eye on the harmful effects of the
therapy causing an over suppression of TSH and thereby affecting the patient.
Subclinical hypothyroidism is seen when the patient has normal level of free
thyroxine in the serum while having their thyroid stimulating hormone in the
serum in excess of the normal value. It is advised to start treatment with
levothyroxine if the patient has thyroid stimulating hormone in the serum more
than 10 mIU/L even if he has got normal levels of free thyroxine in his serum.
These patients clearly have benefits of treatment however for those patients
presenting with values of thyroid stimulating hormone in the serum in the range of
5 to 10 mIU/L it is controversial. The points for starting treatment with
levothyroxine are that subclinical hypothyroid patients frequently land up in
hypothyroidism, there is a positive change in the quality of life and also this
condition can affect the patient’s heart in the long run thereby compromising on
the life expectancy of the patient. However some recent data are showing that the
risk to the heart is seen in subjects less than the age of seventy years; while those
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patients who are between seventy to eighty years have not developing added risk
and finally in those patients above the age of eighty years in fact have the luxury of
protection to the heart due to the treatment. Having seen the pros and cons of
treatment one grey area which needs to be addressed is in those patients who
present with values of serum TSH below ten mIU/L and some multicentered
randomised control studies are necessary to evaluate the efficacy of treating these
patients with levothyroxine. But it does not mean that we should not treat these
patients but the fact is that treatment should be based upon the individual patient
with the treating physician taking a lot of factors like if the patient wants treatment,
if he has got any symptoms or if he has got some co morbid conditions.
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MATERIALS AND METHODS
Case selection
Women above 50 years of age attending Medical outpatient clinic of Chengalpattu
medical college and hospital from January 2012 to june 2012 were studied. The
sample consisted of a random selection of 100 women. Informed consent was
obtained from all participants. All the participants were examined for thyroid
function. Women with subclinical hypothyroidism (defined as TSH > 5.5?IU/ml
with normal free T4 and free T3) were considered as cases, and women without
subclinical hypothyroidism were considered as controls. Laboratory measurements
and clinical assessment was carried out in all the participants.
Exclusion criteria
Those with
Chronic renal failure
Known thyroid disease
History of neck irradiation
Severe illness (such as recent myocardial infarctions, infections, severe heart
failure or recent intensive care admission)
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Taking drugs such as amiodarone, beta-blockers, interferon –?
were excluded
Measurements
All the patient were done Thyroid function test- Free T3, Free T4 and TSH levels.
Thyroid function test is done using the electro chemiluminence method. The
normal range for Free T3 it is 1.70-4.20 pg/ml, for Free T4 it is 0.70-1.80 ng/dl and
for TSH is 0.30-5.50 ?IU/ml.
Clinical Assessments
All the Participants were examined for symptoms related to hypothyroidism and
also for the presence of goiter. Also general examination and clinical examination
of cardiovascular, respiratory, abdominal and central nervous system were made.
Analytical methods
The following data were collected from all the participants
• Age
• Presence of Hypertension (defined as BP > 140/90 mm Hg on more than one
occasion or the patient is known to be hypertensive)
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•  Diabetes  mellitus  (defined  as  fasting  blood  sugar  >  =  126  mg%  on  two
consecutive readings one month apart or the patient is known to be diabetic)
• Ischemic heart disease (defined as angina or myocardial infarction by self report
or by analysis of standard 12 lead ECG for ischemic heart disease changes or
echocardiography)
• Comparison between cases (subclinical hypothyroidism) and normal control
subjects of similar age and ethnic group was done with regard to presence of IHD,
Hypertension and Diabetes mellitus
Statistical Analysis
Statistical analysis was done using the statistical package for social sciences
(SPSS).Different statistical methods were used as appropriate. Mean ± SD was
determined for quantitative data and frequency for categorical variables. The
independent t- test was performed on all continuous variables. The normal
distribution data was checked before any t-test. The Chi-Square test was used to
analyze group difference for categorical variables. In logistic regression models,
age was adjusted for estimation of each or all the independent effects of
hypertension, ischemic heart disease and diabetes mellitus. A p- value < 0.05 was
considered significant.
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RESULTS
100 elderly women above 50 years of age who attended the medical outpatient
clinic of Chengalpattu medical college and hospital during the period of study were
studied and 21 women were found to have the criteria set for the definition of
subclinical hypothyroidism which meant a rate of 21 %. Patients with subclinical
hypothyroidism were regarded as cases and remaining 79 patients were the control
group.
Differences were seen in the mean age distribution among cases and controls are
shown in table 1 and fig 1
                                                         Table 1
  Age in years Patients with SH Patients without SH
50-59 7 36
60-69 8 25
70 and above 6 18
Out of the 43 patients in 50-59 age group 7 ( 16.28% ) of them had subclinical
hypothyroidism. Out of the 33 patients in 60-69 age group 8 ( 24.24% ) of them
had subclinical hypothyroidism. Out of the 24 patients in 70 and above age group 6
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( 25% ) of them had subclinical hypothyroidism. The mean TSH level in patients
with subclinical hypothyroidism was 9.02 ?IU/ml. For FT4 it was 0.90 ng/dl and
for  FT3  it  was  1.83  pg/ml.  Differences  in  FT4,  FT3,  TSH distribution  were  seen
among cases and controls as shown in Table 2 and fig 2
                                                         Table 2
Mean Patients with SH Patients without TSH
FT3 (pg/ml) 1.83 2.30
FT4 (ng/dl) 0.90 1.12
TSH (?IU/ml) 9.02 2.13
There were 21 patients with TSH level more than 5.5 ?IU/ml, the upper level of
normal range ( 0.30-5.5 ?IU/ml). They are the subclinical hypothyroid patients in
this study. Of those 21 patients 14 ( 66.67% ) had TSH level between 5.5 to 10
?IU/ml. The remaining 7 ( 33.33% ) patients had TSH levels more than 10 ?IU/ml
as shown in the following Table 3 and fig 3
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                                                      Table 3
TSH levels in patients with SH
TSH level in ?IU/ml No. of patients(%)
Total no = 21
5.5 – 10 14 ( 66.67 )
> 10 7 ( 33.33 )
Symptoms of hypothyroidism were seen in 6 out of 21 ( 28.57% ) patients with
subclincal hypothyroidism. The most common complaints were fatigability and
constipation, followed by weight gain. The frequency of hypothyroid symptoms in
the subclinical hypothyroid patients are as shown in the table 4 and fig 4
Table 4
 Frequency of hypothyroid symptoms in patients with SH
Fatigability 5 ( 23.81% )
Constipation 5 ( 23.81% )
Weight gain 3 ( 14.29% )
Goiter 2 ( 9.52% )
Others( cold intolerance, infertility
etc)
2 ( 9.52% )
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There was goiter present in 2 out of 21 patients with subclinical hypothyroidism
(9.52%) and 5 out of 79 patients without subclinical hypothyroidism ( 6.3% ).
Other symptoms like cold intolerance infertility were present in 2 of the 21 patients
(9.52%) with subclinical hypothyroidism and 1 of the 79 patients ( 1.2 % ) without
subclinical hypothyroidism. The incidence of risk factors like hypertension
diabetes and ischemic heart disease were compared between patients with
subclinical hypothyroidism and control. They were analyzed independently with
chi-Square test. The p- value showed that patients with subclinical hypothyroidism
were significantly associated with ischemic heart disease compared to controls.
The p- value is not significant for hypertension and diabetes. This is shown in table
5 and fig 5
                                                          Table 5
Patients with
SH
Patients without
SH
p- value
IHD 5 ( 23.81% ) 4 ( 5.06% ) 0.0185
DM 3 ( 14.29% ) 17 ( 21.52% ) 0.5545
HT 5 ( 23.81% ) 22 ( 27.85% ) 0.7892
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DISCUSSION
Subclinical hypothyroidism has high prevalence among elderly women. The
prevalence in elderly ranges from 7 – 26 % in various studies [36-38, 21,24,41-44] with
the highest rate approaching 26% in elderly women [1,9,24,44]. Our study has a
prevalence rate of 21 % which is in concordance with the other studies. Large
number of surveys have shown that the percentage of cases with TSH < 10?IU/ml
in cases of subclinical hypothyroidism is 55-85% [6,24,44,70,71 ]. 66.67% of our cases
with subclinical hypothyroidism had TSH levels < 10?IU/ml. Many studies have
shown that the thyroid antibody test on these patients with increased thyroid
stimulating hormone turned out to be positive in the range of twenty to seventy
eight percent[6,24,44,70,71]. Studies have shown that nearly 30% of the patients with
subclinical hypothyroidism have symptoms of thyroid hormone deficiency [ 37,72 ].
Fatigability and weight gain were the most common symptoms [73], but not all
studies have found his to be true [21]. In concordance with these studies our study
demonstrated 28.57% of patients with subclinical hypothyroidism had symptoms
of thyroid hormone deficiency of which fatigability (23.8%) and constipation
(23.8%) were the most common. On support of  the above findings researchers
who conducted one study in Switzerland with a large number of women like above
300 subjects who had hypothyroidism found out that among 93 patients with
subclinical hypothyroidism 24% of them presented with symptoms seen in
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hypothyroidism [72]. These findings drive home the fact that it is not easy to
diagnose a case of primary hypothyroidism by simply seeing the symptomatology
profile alone. Furthermore people who presented with normal thyroid status and
those with subclinical hypothyroidism cannot be easily found out only based on
symptoms. Even though these studies showing some significant statistics in big
number of people , when it comes to a single patient it is not easy to separate a
person who presents with normal thyroid hormone levels from another person
presenting with either hypothyroidism or subclinical hypothyroidism. There are
five studies which have shown that there is improvement in psychological levels,
symptoms associated with SH and also improvement in life quality[63,74-77]. Out of
the above studies only two resulted in improvement[74,77], while the average thyroid
stimulating hormone values were above 11 mU/L. One of the studies showed only
a mild but significant benefit in the form of difference in the rate of response in the
range of twenty four percent when compared with the placebo and those treated
with thyroxine hormone, furthermore no factors could show who will gain from
thyroid hormone therapy[63]. While there was no advantage of thyroid hormone
therapy shown by the 2 studies which were remaining[75,76]. Out of these 2 studies
one of them showed an improvement in the memory scores due to hormone
therapy on comparison to placebo[75] while the other one but no other included
patients with thyroid stimulating hormone between five to ten micro units per litre
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showed some surprising outcomes. Only few symptoms relating to thyroid
hormone deficiency were made out in the group which was treated with thyroid
hormone and those treated with placebo[76]. Also patients who were in the range of
5-10 mU/L thyroid stimulating hormone were not sure if they are prescribed
thyroid hormone therapy or placebo[76] . Combining the results above from the
trials it can be taken that 1) patients with TSH between 5 to 10 mU/liter did not
gain significantly from thyroid hormone therapy than the patients who were
prescribed placebo, 2) out of those subjects presenting with worser subclinical
hypothyroidism only twenty five percent of them gained from thyroxine hormone
therapy  3) needless use of thyroid hormone therapy would only rarely improve
symptoms associated with thyroid hormone deficiency on the fact that large
number of people with SH have values of  TSH between 5 to 10  mU/liter.
Therefore in subjects presenting with thyroid stimulating hormone in the serum
greater than ten 10 mU/liter, no debate is there and therapy is advised. This is
reasonable because the conversion rate of these subjects into clinical
hypothyroidism is more and LDL is decreased eight percentage with thyroxine
treatment[78].  The treatment  with  thyroxine  in  these  subjects  with  SH can provide
good results with improvement of symptoms and also other systems. In subjects
with thyroid stimulating hormone between five and ten mU/liter there is a
provision for observation or therapy is started with regard to an individual patient.
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The association between subclinical hypothyroidism and coronary heart disease is
still somewhat controversial [24,54,79,80,81]. The Busselton Health Study reported that
subclinical hypothyroidism is an independent risk factor for coronary heart disease
[81]. Also, several studies have shown an association between subclinical
hypothyroidism and either specific age ranges or TSH levels. The Rotterdam Study
[24] showed a higher prevalence of atherosclerotic coronary vascular disease in
female subclinical hypothyroidism patients who were 55 years of age or older.
However, Ochs et al. [54] found in their metaanalysis using population-based cohort
studies that the relative risk of subclinical hypothyroidism for coronary heart
disease was significantly higher in subjects younger than 65 years, but not in
subjects of age 65 years and older. Razvi et al. [82] also  reported  results  from  a
meta-analysis showing that subclinical hypothyroidism is associated with increased
coronary heart disease in subjects from younger populations only. The degree of
subclinical hypothyroidism could be another important factor. subclinical
hypothyroidism subjects with a TSH >=10 mU/l may also have an increased
coronary heart disease risk, and recent data have shown that subclinical
hypothyroidism is associated with an increased risk of coronary heart disease
events and coronary heart disease mortality [54,83]. In addition, the Wickham survey,
a large-scale, long term follow-up study, found no evidence to suggest that
subclinical hypothyroidism is associated with an increased risk of ischemic heart
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disease [23]. Our present study showed a significant increase in IHD in patients with
subclinical hypothyroidism compared with controls (p value of 0.0185 ) . Several
studies on association between subclinical hypothyroidism and dyslipidemia have
been done. A study done by  Althaus et al. [12] found out that the quantity of low
density lipoprotein cholesterol was more while that for high density lipoprotein
cholesterol was less in patients presenting with this condition when they were
compared with people who were euthyroid, after the investigators adjusted for
factors like age of the patient, body mass index and sex. This study[12] shows us the
reason why patients with subclinical hypothyroidism end up having an increased
incidence of affection of the heart in the form of coronary heart disease. One
report[9] from Colorado in which the prevalence of diseases of the thyroid was
studied pointed out that subjects presenting with subclinical hypothyroidism had an
increase in total cholesterol and low density lipoprotein cholesterol which was
significant when compared to euthyroid subjects but there was not much difference
in the levels of triglycerides and high density lipoprotein cholesterol. These results
were similar to other researchers Efstathiadou et al. [84] who also showed that
subjects with subclinical hypothyroidism presented with increased quantity of total
cholesterol and low density lipoprotein cholesterol but not much difference in the
levels of triglycerides and high density cholesterol compared to euthyroid people.
The quantity of lipid in a patient is decided by many things. It has been shown by
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various study works that the hormones released by the thyroid play a role in
changing the cholesterol levels in the patients. These hormones results in more
production of cholesterol by inducing hydroxymethylglutaryl coenzyme A which is
an important enzyme related to the production of cholesterol. There is a more
production of low density lipoprotein cholesterol receptor because low density
lipoprotein cholesterol receptor gene has a thyroid hormone responsive element
which is acted upon by T3 to increase it’s expression[85,86]. Subjects with
hypothyroidism presented with more amount of total cholesterol, triglyceride and
low density lipoprotein cholesterol while they had less high density lipoprotein
cholesterol. This is due to the mechanism given above as said by the investigators
in subclinical hypothyroidism. Patients with subclinical hypothyroidism did not
differ from controls with regard to hypertension and diabetes in previous studies
[87,72]. Our study also proves it true. In data from a cross-sectional study of 2,033
participants carried out by Walsh et al [88], who showed that mean systolic blood
pressure, diastolic blood pressure and the prevalence of hypertension did not differ
significantly between subclinical hypothyroidism and euthyroid subjects.
Similarly, Kvetny et al [89] did not find a significant difference in BP when
comparing 249 patients with SH and 963 patients with normal thyroid hormones
and TSH [89]. In one of the studies called Rotterdam study, no difference in was
detected regarding BP between 124 women with mild subclinical hypothyroidism
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and 931 euthyroid women [24]. Previous studies revealed that the level of fasting
glucose [90,91] and hemoglobin A1C [91] or prevalence of diabetes mellitus [81,92,93]
did not differ between the subclinical hypothyroidism and euthyroid subjects.
Goiter is twice among prevalent in patients with subclinical hypothyroidism [1] and
it is found in 9.5% of our patients. The distribution of  serum TSH values in the
normal population is skewed, with the majority of individuals having TSH values
at the lower end of the normal range [94]. Recent studies have reported that “high
normal” TSH values may be associated with modest increases in serum cholesterol
levels [95-97] and that serum cholesterol levels improve when TSH values are
reduced from the high end to the low end of the normal range with L-thyroxine
supplementation [95]. Furthermore, individuals with high normal serum TSH levels
may have endothelial dysfunction [98]. Thus, although not based on prospective
outcomes data, these findings would suggest to us that the optimal goal TSH range
for L-thyroxine-treated patients is 0.5–2.0 ?U/ml. Also some study conducted in
America showed that treating as well as screening subclinical hypothyroidism in
all  people  above  the  age  of  35  years  is  cost  effective  as  a  lot  of  other  similar
screening modalities done for other diseases in the country[99]. Subclinical
hypothyroidism is quite frequently encountered problem with patients ultimately
ending up in gross hypothyroidism. Subjects with this problem have large number
of somatic symptoms, deficits in areas related to memory, depressed mood, cardiac
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problems like improper functioning of the heart in diastole and systole, increase in
the amount of total lipid and low density lipoprotein predisposing the patient to the
problem of landing him ultimately in atherosclerosis. There are large number
studies which have demonstrated that many of these untoward problems can be
cured or improved if the patients are adequately treated with L- thyroxine
hormone. Also treating these patients with subclinical hypothyroidism is not a
waste of cost compared to the benefits. It is advised that treatment should be given
early in the disease even though the patients do not have symptoms because these
patients eventually end up with the classical symptoms of severe hypothyroidism
because the glands function gradually deteriorates particularly in those subjects
who have antibodies against the thyroid who are more prone to develop
hypothyroidism. Due to these reasons hormone therapy is advised for most of the
subjects presenting with subclinical hypothyroidism with special importance to
subjects presenting with symptoms, risk factors relating to the heart, goitres or
having antibodies against the thyroid gland and in women patients diagnosed with
pregnancy. In spite of the beneficial effects of treating these patients we have to
determine how far these benefits carry an advantage over some of the risks
associated with the therapy because data relating to the outcome are lacking and
also there is a danger of over suppression of Thyroid stimulating hormone in those
on hormone therapy. The potential consequences of untreated mild thyroid failure
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on atherosclerosis in adults and on intellectual potential in infants born to mothers
with mild thyroid failure begs for definitive answers about the therapeutic benefits
of thyroid hormone replacement. It is no longer scientifically or morally justifiable
to argue whether mild thyroid failure is something or nothing. What is clearly
needed now are clean, randomized, prospective, and adequately powered trials to
provide unequivocal answers to the lingering but critical questions regarding the
effects of mild thyroid failure and its treatment on important end points such as
intellectual function, ischemic heart disease, and quality of life.
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Conclusion
• There is a high prevalence of subclinical hypothyroidism in elderly females
above 50 years of age.
• Most of the patients with subclinical hypothyroidism have serum TSH below
10?IU/ml.
• Symptoms of hypothyroidisim was seen in patients with subclinical
hypothyroidism. ( 28.57% of subjects in this study) Fatigability and Constipation
were the most common symptoms.
• Subjects with subclinical hypothyroidism are more susceptible to ischemic heart
disease.
• There is no increased susceptibility to develop diabetes mellitus and hypertension
in subjects with subclinical hypothyroidism.
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APPENDIX
1 BMI Body Mass Index 21 rT3 Reverse T3
2 D1 Type 1 deiodinase 22 RAIU Radio Active Iodine
Uptake
3 D2 Type 2 deiodinase 23 RXR Retinoid X Receptor
4 DIT Diiodothyronine 24 SH Subclinical
Hypothyroidism
5 DUOX Dual Oxidase 25 SLC5A Solute Carrier Family 5A
6  E Embryonic Day 26 T3 Triiodothyronine
7 FSH Follicle Stimulating
Hormone
27 T4 Tetraiodothyronine
8 FT3I Free T3 Index 28 TBAb Thyroid Blocking
Antibody
9 FT4I Free T4 Index 29 TBG Thyroid Binding Globulin
10 hCG Human chorionic
gonadotorpin
30 TgAb Thyroglobulin Auto
antibody
11 HDL High Density
Lipoprotein
31 THBR Thyroid Hormone Binding
Ratio
12 I Iodine 32 THOX Thyroid Hormone
Oxidase
13 IHD Ischemic Heart Disease 33 TPO Thyroid Peroxidase
14 LDL Low Density
Lipoprotein
34 TPOAb Thyroid Peroxidase
Antibody
15 LH Luteinizing Hormone 35 TR Thyroid hormone
Receptor
16 MCR Metabolic Clearance
Rate
36 TRH Thyroid Releasing
Hormone
17 MCT Mono Carboxylate
Anion Transporter
37 TSAb Thyroid Stimulating
Antibody
18 MIT Mono Iodo Thyronine 38 TSH Thyroid Stimulating
Hormone
19 NIS Sodium Iodide
Symporter
39 TSHR TSH Receptor
20 PVN Para Ventricular
Nucleus
40 TTR Transthyretin
PROFORMA
NAME: ADDRESS:
AGE:            SEX:                                                                          OCCUPATION:
HISTORY OF:
1. FATIGABILITY
2. WEIGHT GAIN
3. CONSTIPATION
4. COLD INTOLERANCE
5. DRY SKIN
6. HOARSENESS
7. OTHER SYMPTOMS: SPECIFIED
PAST H/O:
1. SYSTEMIC HYPERTENSION
2. DIABETES MELLITUS
3. CORONARY HEART DISEASE
4. HYPOTHYROIDISM
5. DRUG INTAKE
6. EXPOSURE TO IRRADIATION
7. THYROID SURGERY
PERSONAL H/O:
1. MENSTRUAL HISTORY
2. OBSTRETIC HISTORY
CLINICAL EXAMINATION:
PULSE RATE:                       BLOOD PRESSURE:                    TEMPERATURE:
GOITRE:
 CVS:                                                                                                           RS:
 ABDOMEN:                                                                                        CNS:
INVESTIGATIONS
1. FREE T3, FREE T4, TSH.
2. BLOOD SUGAR – FASTING AND POST PRANDIAL
3. ECG – RATE, RHYTHM, PR INTERVAL, AXIS, BUNDLE BRANCH
BLOCK, ST-T CHANGES, CHAMBER ENLARGEMENT.
4. ECHO
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1 Lakshmi 51 983 No No No No No No No No 72 120 / 70 98.3 2.56 1.22 1.7 88, 134 25 1 No No
2 Thulasi 52 990 No No No No No No No No 77 130 / 80 98.2 2.54 1.14 1.5 90, 140 30 0.9 Yes Yes
3 Rani 52 1537 No No No No No No No No 75 156 / 98 98.4 2.67 1.21 0.7 168, 310 33 0.9 No No
4 Mangammal 53 1539 No No No No No No No No 88 128 / 84 98.3 2.55 1.23 1 89, 128 34 0.8 No No
5 Chandra 52 1543 No No No No No No No No 85 126 / 82 98.5 1.98 0.93 7.9 88, 132 35 0.7 No No
6 Kanchana 70 1550 No No No No No No No Yes 70 130 / 70 98.1 2.86 1.36 1.3 87, 127 32 1 No No
7 Rani 60 1605 No No No No No No No No 90 134 / 84 98.4 2.72 1.38 1.2 84, 130 31 0.9 No No
8 Pushpavalli 54 1666 No No No No No No No No 71 162 / 104 98.5 2.63 1.25 2 78, 110 34 0.8 No No
9 Parvathy 71 1834 No No No No No No No No 79 136 / 86 98.3 1.92 0.92 9.2 74, 112 35 1.1 Yes Yes
10 Paravatha 55 1900 No No No No No No No No 80 126 / 74 98.4 2.58 1.32 1.7 85, 132 36 1.1 No No
11 Kuppama 55 3172 No No No No No No No No 86 110 / 70 98.2 2.27 1.08 1.4 88, 138 36 1 No No
12 Sita 54 3222 No No No No No No No No 92 120 / 80 98.1 2.25 1.09 1.3 142, 266 37 0.9 No No
13 Raguvammal 72 3588 No No No No No No No No 83 158 / 94 98.6 1.76 0.84 1.9 82, 150 37 0.9 No No
14 Kannayi 70 3727 No No No No No No No Yes 88 130 / 80 98.4 1.56 0.98 2 84, 146 38 0.8 No No
15 Alamelu 61 3820 No No No No No No No No 91 132 / 82 98.3 1.68 0.88 8.1 96, 132 25 1 No No
16 Ponnatha 54 3831 No No No No No No No No 77 134 / 86 98.3 2.1 0.86 3.5 88, 134 26 0.9 No No
17 Krishnaveni 62 3837 No No No No No No No No 75 148 / 96 98.6 2.02 0.92 3.2 138, 278 29 0.9 No No
18 Kanagi 72 3840 No No No No No No No No 73 130 / 80 98.2 1.81 0.86 4.4 86, 138 29 0.8 No No
19 Kuttiyamma 65 3846 Yes No Yes No No No No No 70 160 / 100 98.3 1.72 0.88 11 150, 305 30 0.8 No No
20 Punitha 51 3850 No No No No No No No No 75 128 / 76 98.4 1.85 0.89 3.9 88, 134 26 1 No No
21 Paravatham 52 3872 No No No No No No No No 87 158 / 94 98.4 2.29 1.09 1.1 95, 129 32 1.1 No No
22 Prema 52 3888 No No No No No No No No 83 136 / 76 98.5 2.28 1.12 1.1 96, 138 33 1 No No
23 Pattamma 72 3916 Yes Yes Yes Yes No No Infertility Yes 90 166 / 112 98.4 1.74 0.89 14 152, 298 36 0.9 Yes Yes
24 Mekala 53 3920 No No No No No No No No 79 128 / 78 98.3 1.78 0.86 7 82, 119 29 0.9 No No
25 Vasantha 54 3928 No No No No No No No No 73 130 / 84 98.3 2.21 1.05 0.7 84, 120 31 0.8 No No
26 Jaya 56 3940 No No No No No No No No 78 130 / 70 98.5 2.22 1.09 0.9 167, 289 33 1 No No
27 Navaneetham 71 8043 No No No No No No No No 86 166 / 110 98.4 2.18 1.04 2.9 88, 122 27 0.8 No No
28 Jayabarathi 72 8050 No No No No No No No No 85 134 / 88 98.4 1.88 0.92 1.1 145, 264 28 0.8 No No
29 Anjalatchi 66 8075 No No No No No No No No 81 132 / 86 98.3 2.46 1.17 1.4 90, 139 27 0.9 No No
30 Anjanamma 62 8100 No No No No No No No No 75 128 / 76 98.2 1.68 0.84 9.5 145, 284 30 1.1 No No
31 Pushpa 55 8353 No No No No No No No No 85 134 / 80 98.4 2.54 1.22 1.1 88, 110 34 1.1 No No
32 Kala 54 8380 No No No No No No No No 80 160 / 110 98.1 2.58 1.23 1 78, 110 34 1 No No
33 Saroja 55 8616 No No No No No No No No 79 132 / 78 98.2 2.42 1.22 1.3 99, 138 33 0.9 No No
34 Usha 72 8617 No No No No No No No No 87 130 / 80 98.4 1.61 0.81 8.2 100, 148 26 0.9 No No
35 Sengani 63 8618 No No No No No No No No 90 136 / 86 98.2 2.81 1.37 2.6 78, 111 28 0.8 No No
36 Kalaiselvi 54 8632 No No No No No No No No 77 134 / 84 98.3 1.95 0.93 7.2 80, 128 29 0.9 No No
37 Ponnamma 74 8643 No No No No No No No No 76 130 / 80 98.3 2.45 1.45 2.7 79, 96 33 1 No No
38 Gengamma 63 8650 No No No No No No No No 86 128 / 80 98.4 2.37 1.13 3.7 170, 322 32 0.9 No No
39 Nagamma 71 8652 No No No No No No No No 78 130 / 70 98.4 2.42 1.32 3.6 86, 127 31 0.9 No No
40 Christina 54 8659 No No No No No No No No 75 154 / 98 98.2 2.61 1.24 1.9 104, 145 28 0.8 No No
41 Emarose 64 8668 No No No No No No No No 88 110 / 70 98.4 1.85 0.89 9 111, 156 26 0.8 No No
42 Sivagami 55 8682 No No No No No No No No 74 110 / 80 98.5 2.02 0.99 1.1 91, 131 37 1 No No
43 Vallimma 70 8690 No No No No No No No No 73 134 / 86 98.3 2.04 0.97 1 94, 138 34 0.8 No No
44 Paravayi 71 8691 No No No No No No No No 89 160 / 100 98.4 2.12 1.48 2.7 165, 302 33 0.8 No No
45 Chandra 56 8692 No No No No No No No No 72 132 / 78 98.1 2.04 0.97 1 87, 135 28 0.8 No No
46 Ganga 57 8699 No No No No No No No Yes 86 134 / 86 98.2 2.05 1.05 2.3 88, 138 35 0.9 No No
47 Jaya 59 10306 No No No No No No No No 72 130 / 80 98.3 2.35 1.12 3.6 156, 279 36 1 No No
48 Mallika 72 10310 No No No No No No No No 87 158 / 98 98.4 2.84 1.35 1 98, 125 37 0.9 Yes Yes
49 Kasthuri 65 10324 No No No No No No No No 77 138 / 86 98.4 2.48 1.54 2.7 87, 123 38 0.9 No No
50 Dayalu 54 10330 No No No No No No No No 90 152 / 98 98.5 1.75 0.79 10 78, 110 27 0.8 Yes Yes
51 Kanniyamma 64 10353 No No No No No No No No 74 120 / 80 98.6 1.89 0.9 3.2 80, 120 26 0.9 No No
52 Andal 53 10354 No No No No No No No No 78 130 / 80 98.2 2.65 1.12 3.3 92, 110 28 0.9 No No
53 Alamelu 70 10355 No No No No No No No No 89 132 / 78 98.3 1.95 0.93 3.5 160, 288 30 0.8 No No
54 Prathiba 65 10362 No No No No No No No No 78 156 / 96 98.1 2.24 1.02 3.2 86, 108 32 1 No No
55 Subathra 72 10370 No No No No No No No No 74 134 / 78 98.1 1.86 0.96 7.8 89. 144 31 0.9 No No
56 Pothayi 52 10375 No No No No No No No No 82 132 / 84 98.3 2.08 0.99 1.2 74, 101 34 0.8 No No
57 Rajeshwari 66 10384 Yes Yes Yes No No No No No 88 158 / 96 98.4 1.74 0.79 11 76, 98 33 0.8 Yes Yes
58 Thangammal 51 10390 No No No No No No No No 79 110 / 80 98.2 2.04 0.99 1.8 88, 121 32 0.9 No No
59 Saroja 67 13919 No No No No No No No No 78 164 / 104 98.4 2.06 0.98 1.8 88, 124 31 1 No No
60 Meena 68 13920 No No No No No No No Yes 82 120 / 80 98.4 2.12 1.04 2.6 75, 101 29 0.8 No No
61 Pottiammal 52 36138 No No No No No No No No 85 134 / 86 98.5 1.92 0.99 6.8 78, 98 30 0.9 No No
62 Kannatha 53 36777 No No No No No No No No 88 130 / 80 98.2 2.39 1.14 3.2 78, 101 32 0.9 No No
63 Thanammal 67 72554 No No No No No No No No 76 130 / 70 98.4 2.21 1.05 3.1 86, 129 29 0.8 No No
64 Thotiyamma 55 72555 No No No No No No No No 77 170 / 110 98.3 2.01 0.95 2.8 92, 122 29 1 No No
65 Kasthuri 73 72556 No No No No No No No Yes 79 132 / 78 98.3 2.11 0.98 2.6 88, 122 37 0.9 No No
66 Sathya 55 72557 No No No No No No No No 89 134 / 80 98.4 1.98 1.11 7.5 90, 132 33 0.9 No No
67 Sampoorna 68 72558 No No No No No No No No 72 130 / 70 98.2 2.11 1.01 2.6 95, 128 33 0.8 No No
68 Kuruvayi 60 72604 No No No No No No No No 87 130 / 80 98.3 2.14 1.02 2.7 96, 132 34 0.8 No No
69 Malliga 54 72607 No No No No No No No No 78 134 / 80 98.5 2.84 1.35 2.8 79, 105 33 0.9 No No
70 Lalitha 63 72611 No No No Yes No No Infertility No 77 168 / 108 98.5 2.02 0.96 2.6 146, 268 26 0.9 No No
71 Lakshmi 53 72618 No No No No No No No No 77 130 / 78 98.3 2.04 0.97 2.5 82, 123 37 0.9 No No
72 Sampoorani 64 72620 No No No No No No No No 87 120 / 80 98.1 2.22 1.04 3.2 83, 113 35 0.8 No No
73 Kuruvammal 74 72630 No No No No No No No No 82 164 / 106 98.3 2.35 1.12 3.8 80, 132 35 1 No No
74 Murugamma 53 72644 No No No No No No No No 76 136 / 84 98.3 2.24 1.08 3.3 143, 269 34 0.9 No No
75 Rosammal 53 72723 No No No No No No No No 81 122 / 74 98.3 2.15 1.04 3.6 85, 118 35 0.9 No No
76 Rani 66 76292 No No No No No No No No 78 120 / 70 98.4 1.89 0.96 7.7 78, 100 33 0.8 No No
77 Sathyavathi 52 76315 No No No No No No No No 90 134 / 78 98.2 2.67 1.27 1.7 70. 101 32 0.9 No No
78 Indira 67 76316 No No No No No No No No 78 132 / 86 98.3 2.45 1.22 1.7 76, 105 33 0.9 No No
79 Jayammal 53 76320 No No No No No No No No 88 172 / 116 98.1 2.86 1.36 2.4 86, 118 31 0.8 No No
80 Irusammal 62 76327 No No No No No No No No 86 120 / 70 98.4 2.12 1.24 2.3 178, 320 30 1 No No
81 Kannatha 61 76331 No No No No No No No No 87 130 / 70 98.5 2.56 1.22 0.6 90, 136 33 1 No No
82 Baby 72 80647 Yes Yes Yes No No No Infertility Yes 73 168 / 114 98.2 1.76 0.78 12 94, 135 29 0.9 Yes Yes
83 Chellayi 54 80650 No No No No No No No No 71 132 / 78 98.3 2.47 1.12 0.7 166, 297 28 0.8 No No
84 Ranganayaki 55 80751 No No No No No No No No 81 168 / 108 98.4 2.42 1.15 1 96, 142 29 0.8 No No
85 Theerthamal 71 80755 No No No No No No No No 86 120 / 80 98.5 2.82 1.26 0.9 78, 98 34 0.9 Yes Yes
86 Annammal 61 80792 No No No No No No No No 87 136 / 86 98.3 2.12 1.01 1.5 94, 132 34 0.9 No No
87 Sellammal 60 80793 No No No No No No No No 85 156 / 94 98.4 2.15 1.02 1.3 92, 123 35 0.8 No No
88 Selvi 61 80794 No No No No No No No No 72 122 / 78 98.3 1.92 1.08 6.8 85, 116 29 0.9 No No
89 Mangayi 72 80799 No No No No No No No No 76 110 / 76 98.4 2.18 1.04 0.6 86, 107 28 0.9 No No
90 Pattammal 62 80860 No No No No No No No No 80 110 / 70 98.5 2.14 1.06 0.8 140, 286 29 0.9 No No
91 Valarmathy 71 80868 No No No No No No No No 78 162 / 104 98.4 1.83 0.87 3.6 98, 125 32 0.8 No No
92 Nagammal 63 80870 No No No No No No No No 74 134 / 78 98.4 2.22 1.15 4 144, 278 34 1 No No
93 Nallatha 56 80888 No No No Yes No No No No 88 130 / 80 98.3 1.75 0.83 10 72, 104 34 0.9 No No
94 Sarojini 72 89361 No No No No No No No No 76 130 / 70 98.4 2.05 0.98 6.9 97, 122 35 0.8 No No
95 Rosayi 62 89365 No No No No No No No No 70 154 / 96 98.4 2.21 1.05 3.5 92, 122 33 0.9 No No
96 Dilliammal 61 89370 No No No No No No No No 76 132 / 78 98.3 2.33 1.11 4 156, 298 34 0.9 No No
97 Chellathayi 62 89379 No No No No No No No No 89 120 / 70 98.5 2.01 0.95 1.9 98, 132 29 0.8 Yes Yes
98 Chinnaponnu 53 89380 No No No No No No No No 78 148 / 94 98.2 2.71 1.29 1 89, 127 29 0.8 No No
99 Durga 63 89392 Yes No Yes No No No No No 90 138 / 86 98.3 1.82 0.89 11 88, 120 32 0.8 No No
100 Thinusammal 71 89395 No No No No No No No No 88 156 / 98 98.4 2.98 1.42 1 134, 264 33 0.9 No No
